0001193125-22-218740.txt : 20220811 0001193125-22-218740.hdr.sgml : 20220811 20220811172714 ACCESSION NUMBER: 0001193125-22-218740 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Frazier Lifesciences Acquisition Corp CENTRAL INDEX KEY: 0001828326 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39765 FILM NUMBER: 221157031 BUSINESS ADDRESS: STREET 1: TWO UNION SQUARE, 601 UNION STREET STREET 2: SUITE 3200 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 617-570-8364 MAIL ADDRESS: STREET 1: TWO UNION SQUARE, 601 UNION STREET STREET 2: SUITE 3200 CITY: SEATTLE STATE: WA ZIP: 98101 10-Q 1 d386684d10q.htm 10-Q 10-Q
false0001828326Q2--12-31WA 0001828326 2021-12-31 0001828326 2022-06-30 0001828326 2021-01-01 2021-06-30 0001828326 2022-01-01 2022-06-30 0001828326 2021-04-01 2021-06-30 0001828326 2022-04-01 2022-06-30 0001828326 2021-01-01 2021-03-31 0001828326 2022-01-01 2022-03-31 0001828326 2020-12-11 0001828326 2020-12-11 2020-12-11 0001828326 2020-12-31 0001828326 2021-06-30 0001828326 2021-03-31 0001828326 2022-03-31 0001828326 us-gaap:CommonClassBMember 2022-06-30 0001828326 us-gaap:CommonClassAMember 2022-06-30 0001828326 flac:ClassACommonStockSubjectToPossibleRedemptionMember 2022-06-30 0001828326 flac:ClassACommonStockAndOneThirdOfOneRedeemableWarrantMember us-gaap:PrivatePlacementMember 2022-06-30 0001828326 srt:MinimumMember 2022-06-30 0001828326 flac:InvestmentsHeldInTrustAccountMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001828326 flac:InvestmentsHeldInTrustAccountMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member flac:InvestmentsHeldInTrustAccountMember 2022-06-30 0001828326 flac:DerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001828326 flac:DerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member flac:DerivativeWarrantLiabilitiesMember 2022-06-30 0001828326 flac:PublicWarrantsMember 2022-06-30 0001828326 flac:ShareTriggerPriceThreeMember 2022-06-30 0001828326 flac:ShareTriggerPriceTwoMember 2022-06-30 0001828326 flac:ShareTriggerPriceOneMember 2022-06-30 0001828326 flac:WorkingCapitalLoanMember 2022-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2022-06-30 0001828326 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2021-04-01 2021-06-30 0001828326 us-gaap:CommonClassAMember 2021-04-01 2021-06-30 0001828326 us-gaap:CommonClassBMember 2021-04-01 2021-06-30 0001828326 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2022-04-01 2022-06-30 0001828326 us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001828326 us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001828326 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001828326 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001828326 flac:ClassACommonStockAndOneThirdOfOneRedeemableWarrantMember us-gaap:PrivatePlacementMember 2022-01-01 2022-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2022-01-01 2022-06-30 0001828326 us-gaap:CapitalUnitsMember 2022-01-01 2022-06-30 0001828326 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001828326 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001828326 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001828326 us-gaap:OverAllotmentOptionMember us-gaap:CommonClassAMember 2020-12-11 2020-12-11 0001828326 us-gaap:IPOMember us-gaap:CommonClassAMember 2020-12-11 2020-12-11 0001828326 us-gaap:CommonClassAMember 2020-12-11 0001828326 flac:FounderSharesMember 2020-10-07 2020-10-07 0001828326 us-gaap:CommonClassBMember flac:FounderSharesMember 2020-10-07 2020-10-07 0001828326 flac:RelatedPartyLoanMember 2020-10-07 2020-10-07 0001828326 flac:FounderSharesMember 2020-11-20 0001828326 us-gaap:CommonClassBMember flac:FounderSharesMember 2020-12-07 0001828326 us-gaap:CommonClassBMember 2020-12-07 0001828326 us-gaap:CommonClassBMember flac:FounderSharesMember 2020-12-08 0001828326 us-gaap:CommonClassAMember srt:MinimumMember 2020-12-08 0001828326 us-gaap:CommonClassBMember 2020-12-08 0001828326 flac:WorkingCapitalLoanMember 2020-10-07 0001828326 flac:RelatedPartyLoanMember 2020-10-07 0001828326 us-gaap:CommonClassBMember 2020-10-07 0001828326 us-gaap:CommonClassBMember 2021-12-31 0001828326 us-gaap:CommonClassAMember 2021-12-31 0001828326 flac:ClassACommonStockSubjectToPossibleRedemptionMember 2021-12-31 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member flac:InvestmentsHeldInTrustAccountMember 2021-12-31 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member flac:InvestmentsHeldInTrustAccountMember 2021-12-31 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member flac:InvestmentsHeldInTrustAccountMember 2021-12-31 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member flac:DerivativeWarrantLiabilitiesMember 2021-12-31 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member flac:DerivativeWarrantLiabilitiesMember 2021-12-31 0001828326 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member flac:DerivativeWarrantLiabilitiesMember 2021-12-31 0001828326 flac:PrivatePlacementWarrantsMember 2021-12-31 0001828326 flac:WorkingCapitalLoanMember 2021-12-31 0001828326 flac:AdministrationAndSupportServicesMember 2021-12-31 0001828326 flac:AdministrationAndSupportServicesMember 2021-01-01 2021-06-30 0001828326 us-gaap:CommonClassAMember 2021-01-01 2021-06-30 0001828326 us-gaap:CommonClassBMember 2021-01-01 2021-06-30 0001828326 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001828326 us-gaap:IPOMember 2021-01-01 2021-12-31 0001828326 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001828326 flac:PipeSharesMember us-gaap:SubsequentEventMember 2022-07-25 2022-07-25 0001828326 flac:PipeSharesMember us-gaap:SubsequentEventMember 2022-07-25 0001828326 us-gaap:CapitalUnitsMember 2022-08-11 0001828326 us-gaap:CommonClassAMember 2022-08-11 0001828326 us-gaap:CommonClassBMember 2022-08-11 0001828326 us-gaap:RetainedEarningsMember 2021-06-30 0001828326 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-06-30 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-06-30 0001828326 us-gaap:RetainedEarningsMember 2022-06-30 0001828326 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-06-30 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-06-30 0001828326 us-gaap:RetainedEarningsMember 2020-12-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2020-12-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2020-12-31 0001828326 us-gaap:RetainedEarningsMember 2021-03-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-03-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-03-31 0001828326 us-gaap:RetainedEarningsMember 2021-12-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-12-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001828326 us-gaap:RetainedEarningsMember 2022-03-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-03-31 0001828326 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-03-31 iso4217:USD xbrli:shares utr:Day xbrli:pure utr:Month utr:Year iso4217:USD xbrli:shares iso4217:EUR xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
                    
to
                    
Commission File Number:
001-39765
 
 
FRAZIER LIFESCIENCES ACQUISITION CORPORATION
(Exact name of registrant as specified in its charter)
 
 
 
     
Cayman Islands
 
98-1562203
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
   
Two Union Square
601 Union St., Suite 3200, Seattle, WA
 
98101
(Address Of Principal Executive Offices)
 
(Zip Code)
(206)
621-7200
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
 
         
Title of each class
 
Trading
symbol(s)
 
Name of each exchange
on which registered
Units, each consisting of one Class A ordinary share and
one-third
of a Warrant to acquire one Class A ordinary share
 
FLACU
 
The Nasdaq Capital Market LLC
Class A ordinary shares, par value $0.0001 per share
 
FLAC
 
The Nasdaq Capital Market LLC
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
 
FLACW
 
The Nasdaq Capital Market LLC
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    
Yes
  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    
Yes
  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
             
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
     Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  
    No  ☐
As of August 11, 2022
,
14,301,000
Units, each Unit consisting of one Class A ordinary share and
one-third
of one Public Warrant,
14,301,000
Class A ordinary shares, par value $0.0001 per share, and
3,450,000
Class B ordinary shares, par value $0.0001 per share, 4,600,000 Public Warrants, and 167,000 Private Warrants, were issued and outstanding.
 
 
 

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Quarterly Report on Form
10-Q
Table of Contents
 
             
         
Page
 
   
PART I. FINANCIAL INFORMATION
        
     
Item 1.
   Condensed Interim Financial Statements      1  
     
     Condensed Balance Sheets as of June 30, 2022 (Unaudited) and December 31, 2021      1  
     
     Unaudited Condensed Statements of Operations for the three and six months ended June 30, 2022 and 2021      2  
     
     Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the three and six months ended June 30, 2022 and 2021      3  
     
     Unaudited Condensed Statements of Cash Flows for the six months ended June 30, 2022 and 2021      4  
     
     Notes to Unaudited Condensed Financial Statements      5  
     
Item 2.
   Management’s Discussion and Analysis of Financial Condition and Results of Operations      20  
     
Item 3.
   Quantitative and Qualitative Disclosures About Market Risk      24  
     
Item 4.
   Controls and Procedures      24  
   
PART II. OTHER INFORMATION
        
     
Item 1.
   Legal Proceedings      25  
     
Item 1A.
   Risk Factors      25  
     
Item 2.
   Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities      26  
     
Item 3.
   Defaults Upon Senior Securities      26  
     
Item 4.
   Mine Safety Disclosures      26  
     
Item 5.
   Other Information      26  
     
Item 6.
   Exhibits      26  
 

PART I. FINANCIAL INFORMATION
Item 1. Condensed Interim Financial Statements
FRAZIER LIFESCIENCES ACQUISITION CORPORATION
CONDENSED BALANCE SHEETS
 
    
June 30, 2022
   
December 31, 2021
 
    
(Unaudited)
       
Assets:
    
Current assets:
    
Cash
   $ 615,440     $ 1,226,716  
Prepaid expenses
     149,722       261,333  
  
 
 
   
 
 
 
Total current assets
     765,162       1,488,049  
Investments held in Trust Account
     138,132,977       138,017,009  
  
 
 
   
 
 
 
Total Assets
  
$
 138,898,139
 
 
$
 139,505,058
 
  
 
 
   
 
 
 
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit:
    
Current liabilities:
    
Accounts payable
   $ 50,698     $ 167,324  
Accrued expenses
     1,783,891       54,750  
  
 
 
   
 
 
 
Total current liabilities
     1,834,589       222,074  
Deferred underwriting commissions
     4,830,000       4,830,000  
Derivative warrant liabilities
     381,360       2,812,530  
  
 
 
   
 
 
 
Total liabilities
     7,045,949       7,864,604  
Commitments and Contingencies
    
Class A ordinary shares subject to possible redemption, $0.0001 par value; 13,800,000 shares issued and outstanding at redemption value of approximately $10.00 per share at June 30, 2022 and December 31, 2021
     138,032,977       138,000,000  
Shareholders’ Deficit:
    
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at June 30, 2022 and December 31, 2021
     —         —    
Class A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; 501,000 shares issued and outstanding (excluding 13,800,000 shares subject to possible redemption) at June 30, 2022 and December 31, 2021
     50       50  
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,450,000 shares issued and outstanding at June 30, 2022 and December 31, 2021
     345       345  
Additional
paid-in
capital
                  
Accumulated deficit
     (6,181,182     (6,359,941
  
 
 
   
 
 
 
Total shareholders’ deficit
     (6,180,787     (6,359,546
  
 
 
   
 
 
 
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
  
$
138,898,139
 
 
$
139,505,058
 
  
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
1

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
 
    
For The Three Months Ended
June 30,
   
For The Six Months Ended
June 30,
 
    
2022
   
2021
   
2022
   
2021
 
General and administrative expenses
   $ 1,960,784     $ 275,239     $ 2,275,402     $ 482,480  
Administrative expenses—related party
     30,000       30,000       60,000       60,000  
  
 
 
   
 
 
   
 
 
   
 
 
 
Loss from operations
     (1,990,784     (305,239     (2,335,402     (542,480
Other income (expenses):
        
Interest income from investments held in Trust Account
     102,847       7,019       115,968       11,466  
Change in fair value of derivative warrant liabilities
     715,050       (1,001,070     2,431,170       2,049,810  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net income (loss)
   $ (1,172,887   $ (1,299,290   $ 211,736     $ 1,518,796  
  
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average number of Class A ordinary shares—basic and diluted
     14,301,000       14,301,000       14,301,000       14,301,000  
  
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted net income (loss) per share, Class A ordinary shares
   $ (0.07   $ (0.07   $ 0.01     $ 0.09  
  
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average number of Class B ordinary shares—basic and diluted
     3,450,000       3,450,000       3,450,000       3,450,000  
  
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted net income (loss) per share, Class B ordinary shares
   $ (0.07   $ (0.07   $ 0.01     $ 0.09  
  
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of th
e
se unaudited condensed financial statements.
 
2

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022
 
    
Ordinary Shares
    
Additional
Paid-in

Capital
          
Total
Shareholders’
Deficit
 
    
Class A
    
Class B
    
Accumulated
Deficit
 
    
Shares
    
Amount
    
Shares
    
Amount
 
Balance—December 31, 2021
  
 
501,000
 
  
$
50
 
  
 
3,450,000
 
  
$
345
 
  
$
  
 
  
$
(6,359,941
 
$
(6,359,546
Net income
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
     1,384,623       1,384,623  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance—March 31, 2022 (Unaudited)
     501,000        50        3,450,000        345                  (4,975,318     (4,974,923
Increase in redemption value of Class A ordinary shares subject to possible redemption
     —          —          —          —          —          (32,977     (32,977
Net loss
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
     (1,172,887     (1,172,887
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance—June 30, 2022 (Unaudited)
  
 
501,000
 
  
$
50
 
  
 
3,450,000
 
  
$
345
 
  
$
  
 
  
$
(6,181,182
 
$
(6,180,787
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021
 
    
Ordinary Shares
    
Additional
Paid-in

Capital
          
Total
Shareholders’
Deficit
 
    
Class A
    
Class B
    
Accumulated
Deficit
 
    
Shares
    
Amount
    
Shares
    
Amount
 
Balance—December 31, 2020
  
 
501,000
 
  
$
50
 
  
 
3,450,000
 
  
$
345
 
  
$
  
 
  
$
(10,538,468
 
$
(10,538,073
Net income
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
     2,818,086       2,818,086  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance—March 31, 2021 (Unaudited)
     501,000        50        3,450,000        345                  (7,720,382     (7,719,987
Net loss
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
     (1,299,290     (1,299,290
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance—June 30, 2021 (Unaudited)
  
 
501,000
 
  
$
50
 
  
 
3,450,000
 
  
$
345
 
  
$
  
 
  
$
(9,019,672
 
$
(9,019,277
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
The accompanying notes are an integral part of th
e
se unaudited condensed financial statements.
 
3
FRAZIER LIFESCIENCES ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS
 
    
For The Six Months Ended
June 30,
 
  
2022
   
2021
 
Cash Flows from Operating Activities:
    
Net income
   $ 211,736     $ 1,518,796  
Adjustments to reconcile net income to net cash used in operating activities:
    
Interest income from investments held in Trust Account
     (115,968     (11,466
Change in fair value of derivative warrant liabilities
     (2,431,170     (2,049,810
Changes in operating assets and liabilities:
    
Prepaid expenses
     111,611       85,863  
Accounts payable
     (116,626     (97,798
Accrued expenses
     1,774,141       (22,268
Due to related party
              1,087  
  
 
 
   
 
 
 
Net cash used in operating activities
     (566,276     (575,596
  
 
 
   
 
 
 
Cash Flows from Financing Activities:
    
Offering costs paid
     (45,000         
  
 
 
   
 
 
 
Net cash used in financing activities
     (45,000         
  
 
 
   
 
 
 
Net change in cash
     (611,276     (575,596
Cash—beginning of the period
     1,226,716       1,365,094  
  
 
 
   
 
 
 
Cash—end of the period
  
$
615,440
 
 
$
789,498
 
  
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
4

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1—Description of Organization, Business Operations and Basis of Presentation
Organization and General
Frazier Lifesciences Acquisition Corporation (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 7, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”).
As of June 30, 2022, the Company had not yet commenced operations. All activity for the period from October 7, 2020 (inception) through June 30, 2022 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and after the Initial Public Offering, the search for a target business. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering.
The Company’s Sponsor is Frazier Lifesciences Sponsor LLC, a Cayman Islands limited liability company (“Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on December 8, 2020. On December 11, 2020, the Company consummated its Initial Public Offering of 13,800,000 units (each, a “Unit” and collectively, the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), including 1,800,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $138.0 million, and incurring offering costs of approximately $8.1 million, inclusive of approximately $4.8 million in deferred underwriting commissions (See Note 6).
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 501,000 units (each, a “Private Placement Unit” and collectively, the “Private Placement Units”), at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of approximately $5.0 million (See Note 4).
Upon the closing of the Initial Public Offering and the Private Placement, approximately $138.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule
2a-7
promulgated under the Investment Company Act which will be invested only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding taxes payable on interest earned) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target business or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act.
The Company will provide the holders of the Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned
 
5

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The
per-share
amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). These Public Shares will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC Topic 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the Amended and Restated Memorandum and Articles of Association which was adopted by the Company at the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 5) prior to this Initial Public Offering (the “Initial Shareholders”) agreed to vote their Founder Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares, private placement shares (the “Private Placement Shares”) underlying the Private Placement Units and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor.
Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company.
The Company’s Sponsor, officers or directors agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company’s obligation to allow the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or December 11, 2022, agreement in principle or definitive agreement for an initial Business Combination within 24 months from the closing of the Initial Public Offering (the “Combination Period”), or (B) with respect to any other provisions relating to shareholders’ rights or
pre-initial
Business Combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment.
If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares, at a
per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
 
6

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
In connection with the redemption of 100% of the Company’s outstanding Public Shares for a portion of the funds held in the Trust Account, each holder will receive a full pro rata portion of the amount then in the Trust Account, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes payable (less taxes payable and up to $100,000 of interest to pay dissolution expenses). The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution in the Trust Account will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There can be no guarantee that the Company will be successful in obtaining such waivers from its targeted vendors and service providers.
Risks and Uncertainties
Management continues to evaluate the impact of the
COVID-19
pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these unaudited condensed financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements.
Liquidity and Going Concern
As of June 30, 2022, the Company had approximately $615,000 in its operating bank account, and working capital deficit of approximately $1.1 million.
 
7

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
The Company’s liquidity needs to date have been satisfied through a contribution of $25,000 from Sponsor to cover for certain expenses in exchange for the issuance of the Founder Shares, the loan of approximately $83,000 from the Sponsor under the Note (as defined in Note 5), and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company repaid the Note in full on December 14, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 5). As of June 30, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loan.
Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. However, in connection with the company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”)
2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December 11, 2022. The condensed financial statements do not include any adjustment that might be necessary if the company is unable to continue as a going concern. Management intends to complete the Business Combination prior to the liquidation date.
Note 2—Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022, or any future period.
The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form
10-K
filed by the Company with the SEC on March 25, 2022.
Emerging Growth Company
As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the Jumpstart our Business Startups Act of 2021 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
 
8

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.​​​​​​​
Use of Estimates
The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2022 and December 31, 2021.
Investments Held in the Trust Account
The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheets, primarily due to their short-term nature, except for the derivative warrant liabilities (see Note 8).
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
9

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Offering Costs Associated with the Initial Public Offering
Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities are expensed as incurred, presented as other expenses in the statement of operations. Offering costs associated with the Public Shares were charged against the carrying value of the Class A ordinary shares subject to redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Derivative Warrant Liabilities
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Subtopic
815-15
“Derivatives and Hedging-Embedded Derivatives” (“ASC Subtopic
815-15”).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
re-assessed
at the end of each reporting period.
The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (as defined in Note 4) are recognized as derivative liabilities in accordance with “Derivatives and Hedging-Contracts in Entity’s Own Equity” (“ASC Subtopic
815-40”).
Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to
re-measurement
at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and have subsequently been measured based on the listed market price of such warrants.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, respectively, outside of the shareholders’ deficit section of the Company’s balance sheets.
 
10

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
Under ASC
480-10-S99,
the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional
paid-in
capital (to the extent available) and accumulated deficit.
Income Taxes
ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) per Ordinary Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. This presentation assumes a business combination as the most likely outcome. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period.
The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the over-allotment) and the Private Placement Warrants to purchase an aggregate of 4,767,000 Class A ordinary shares in the calculation of diluted income per share, because their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the three and six months ended June 30, 2022 and 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.
 
11

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares:
 
 
  
For the Three Months Ended June 30,
 
 
  
2022
 
 
2021
 
 
  
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
Basic and diluted net loss per ordinary share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numerator:
                              
 
Allocation of net loss
  
$
(944,930  
$
(227,957  
$
(1,046,766  
$
(252,524
Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per ordinary share
  
$
(0.07  
$
(0.07  
$
(0.07  
$
(0.07
    
 
 
   
 
 
   
 
 
   
 
 
 
 
 
  
For the Six Months Ended June 30,
 
 
  
2022
 
  
2021
 
 
  
Class A
 
  
Class B
 
  
Class A
 
  
Class B
 
Basic and diluted net income per ordinary share:
                                 
 
Numerator:
                                 
 
Allocation of net income
  
$
170,584    
$
41,152    
$
1,223,610    
$
 
295,186  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Denominator:
                                 
 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net income per ordinary share
   $ 0.01     $ 0.01     $ 0.09     $ 0.09  
    
 
 
   
 
 
   
 
 
   
 
 
 
Recent Issued Accounting Standards
In June 2022, the FASB issued ASU
2022-03,
ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the condensed financial statements.
The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying condensed financial statements.
Note 3—Initial Public Offering
On December 11, 2020, the Company consummated its Initial Public Offering of 13,800,000 Units, including 1,800,000 Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $138.0 million, and incurring offering costs of approximately $8.1 million, inclusive of approximately $4.8 million in deferred underwriting commissions.
Each Unit consists of one Class A ordinary share and
one-third
of one Public Warrant. Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 7).
Note 4—Private Placement
Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 501,000 Private Placement Units, at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of approximately $5.0 million.
 
12

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
Each Private Placement Unit consists of one Class A ordinary share and
one-third
of one redeemable warrant. Each whole private placement warrant underlying the Private Placement Units (the “Private Placement Warrants”) is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Units will expire worthless. The Private Placement Warrants will be
non-redeemable
except as described below in Note 7 and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units until 30 days after the completion of the initial Business Combination.
Note 5—Related Party Transactions
Founder Shares
On October 7, 2020, the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 2,875,000 Class B ordinary shares (the “Founder Shares”). On November 20, 2020, the Sponsor transferred 30,000 Founder Shares to each of the directors other than the Chairman. On December 8, 2020, the Company effected a share
sub-division,
resulting in an increase in the total number of Founder Shares outstanding from 2,875,000 to 3,450,000 shares. All shares and associated amounts have been retroactively restated to reflect the share
sub-division.
The Sponsor agreed to forfeit up to an aggregate of 450,000 Founder Shares to the extent that the option to purchase additional units was not exercised in full by the underwriters so that the Founder Shares would represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters fully exercised the over-allotment option on December 11, 2020; thus, these Founder Shares were no longer subject to forfeiture.
The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share
sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Related Party Loans
On October 7, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is
non-interest
bearing, unsecured and due upon the closing of the Initial Public Offering. The Sponsor paid an aggregate of approximately $83,000 to cover for the Company’s expenses under the Note. On December 14, 2020, the Company fully repaid the Note. The facility is no longer available to be drawn.
In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into private placement units of the post Business Combination entity at a price of $10.00 per unit. The private placement units would be identical to the public units sold, subject to certain limited exceptions. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of June 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans.
 
13

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
Administrative Services Agreement
The Company entered into an agreement that provided that, commencing on the date that the Company’s securities were first listed on the Nasdaq through the earlier of consummation of the initial Business Combination and the liquidation, the Company agreed to pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to the Company. During the three months ended June 30, 2022 and 2021, the Company incurred approximately $30,000 for expenses in connection with the Administrative Services Agreement. During the six months ended June 30, 2022 and 2021, the Company incurred approximately $60,000 for expenses in connection with the Administrative Services Agreement. As of June 30, 2022 and December 31, 2021, we had no amounts payable for such services.
In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any
out-of-pocket
expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, officers or directors, or the Company’s or their affiliates. Any such payments prior to an initial Business Combination will be made from funds held outside the Trust Account.
Note 6—Commitments and Contingencies
Registration and Shareholder Rights
The holders of the Founder Shares, Private Placement Units, Private Placement Shares, Private Placement Warrants, Class A ordinary shares underlying the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The Company granted the underwriters a
45-day
option from the date of the prospectus relating to the Initial Public Offering to purchase up to 1,800,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. The underwriters fully exercised the over-allotment option on December 11, 2020.
The underwriters were entitled to an underwriting discount of $0.20 per unit, or approximately $2.8 million in the aggregate, which was paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $4.8 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Note 7—Class A Ordinary Shares Subject To Possible Redemption
The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 479,000,000 ordinary shares with a par value of $0.0001 per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. As of June 30, 2022 and December 31, 2021, there were 14,301,000 Class A ordinary shares issued and outstanding, of which 13,800,000 shares were subject to possible redemption have been classified as temporary equity.
 
14

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table:
 
Gross proceeds
   $  138,000,000  
Less:
  
Fair value of Public Warrants at issuance
     (7,682,000
Offering costs allocated to Class A ordinary shares subject to possible redemption
     (7,653,636
Plus:
  
Accretion on Class A ordinary shares subject to possible redemption amount
     15,335,636  
  
 
 
 
Accretion on Class A ordinary shares subject to possible redemption, December 31, 2021
     138,000,000  
Increase in redemption value of Class A ordinary shares subject to possible redemption
     32,977  
  
 
 
 
Class A ordinary shares subject to possible redemption, June 30, 2022
   $ 138,032,977  
  
 
 
 
Note 8—Derivative Warrant Liabilities
As of June 30, 2022 and December 31, 2021, the Company has 4,600,000 and 167,000 Public Warrants and Private Placement Warrants, respectively, outstanding.
Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under certain circumstances). The Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by the Initial Shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the
10-trading
day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the
 
15

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price (and the $10.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price see “Redemption of warrants for cash when the price per class A ordinary share equals or exceeds $18.00” and “Redemption of warrants for Class A ordinary shares when the price per class A ordinary share equals or exceeds $10.00” as described below).
The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except (i) that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (ii) except as described below, the Private Placement Warrants will be
non-redeemable
so long as they are held by the Sponsor or such its permitted transferees and (iii) the Sponsor or its permitted transferees will have the option to exercise the Private Placement Warrants on a cashless basis and have certain registration rights. If the Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by such holders on the same basis as the Public Warrants.
Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00:
Once the warrants become exercisable, the Company may call the outstanding warrants for redemption (except as described herein with respect to the Private Placement Warrants):
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
   
if, and only if, the last reported sales price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share
sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a
30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”).
The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the
30-day
redemption period. If and when the warrants become redeemable by the Company, it may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00:
After the warrants become exercisable, the Company may redeem the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of Class A ordinary shares to be determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares;
 
   
if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted per share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and
 
16

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
   
if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), then the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder’s ability to cashless exercise its warrants) as the outstanding Public Warrants as described above.
The “fair market value” of Class A ordinary shares for the above purpose shall mean the volume weighted average price of Class A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment).
In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
Note 9—Shareholders’ Deficit
Preference Shares
- The Company is authorized to issue
1,000,000
preference shares with a par value of $
0.0001
per share. At June 30, 2022 and December 31, 2021, there were
no
preference shares issued or outstanding.
Class
 A Ordinary Shares
- The Company is authorized to issue
479,000,000
Class A ordinary shares with a par value of $
0.0001
per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were
14,301,000
Class A ordinary shares issued and outstanding, of which
13,800,000
shares were subject to possible redemption have been classified as temporary equity (see Note 7).
Class
 B Ordinary Shares
- The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. On October 7, 2020, the Company issued 2,875,000 Class B ordinary shares. On December 8, 2020, the Company effected a share
sub-division,
resulting in an increase in the total number of Class B ordinary shares outstanding from 2,875,000 to 3,450,000 shares. All shares and associated amounts have been retroactively restated to reflect the share
sub-division.
Of the 3,450,000 Class B ordinary shares outstanding, up to 450,000 shares were subject to forfeiture, to the Company by the Initial Shareholders for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the Initial Shareholders would collectively own 20% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering (excluding the Private Placement Shares and assuming the initial shareholders do not purchase any units in the Initial Public Offering). The underwriters fully exercised the over-allotment option on December 11, 2020; thus, these 450,000 Class B ordinary shares were no longer subject to forfeiture. At June 30, 2022 and December 31, 2021, there were
3,450,000
Class B ordinary shares issued and outstanding period. Class A and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the appointment of directors. Holders of the Public Shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason. The provisions of the Amended and Restated Memorandum and Articles of Association governing the appointment or removal of directors prior to the initial Business Combination may only be amended by a special resolution passed by holders representing at least
two-thirds
of the issued and outstanding Class B ordinary shares.
The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of (i) the total number of ordinary shares (excluding the Private Placement Shares) issued and outstanding upon the consummation of the Initial Public Offering, plus (ii) the sum of the total number of Class A ordinary shares issued
 
17

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination (net of any redemptions of Class A ordinary shares by Public Shareholders), excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Units issued to the Sponsor, members of the founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
Note 10—Fair Value Measurements
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.
June 30, 2022
 
Description
  
Quoted Prices
in
Active Markets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Other
Unobservable
Inputs
(Level 3)
 
Assets:
                          
Investments held in Trust Account
   $ 138,132,977      $         $     
Liabilities:
                          
Derivative warrant liabilities
   $      $ 381,360      $     
December 31, 2021
 
Description
  
Quoted Prices
in
Active Markets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Other
Unobservable
Inputs
(Level 3)
 
Assets:
                          
Investments held in Trust Account
   $ 138,017,009      $         $     
Liabilities:
                          
Derivative warrant liabilities
   $ 2,714,000      $ 98,530      $     
Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants of $7,084,000 transferred from a Level 3 measurement to a Level 1 fair value measurement in January 2021, when the Public Warrants were separately listed and traded. The estimated fair value of the Private Warrants of $257,180 was transferred from a Level 3 measurement to a Level 2 fair value measurement in January 2021, as the transfer of Private Placement Warrants to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant.
The estimated fair value of Public Warrants was transferred from a Level 1 measurement to a Level 2 measurement due to lack of trading activity as of June 30, 2022. There were no other transfers to/from Levels 1, 2, and 3 during the six months ended June 30, 2022.
For the three and six months ended June 30, 2022, the Company recognized a gain in the unaudited condensed statements of operations resulting from a decrease in fair value of the derivative warrant liabilities of approximately $
715,000
and $
2.4
 million, respectively, presented as change in fair value of derivative warrant liabilities in the accompanying unaudited condensed statements of operations.
Level 1 instruments include investments in mutual funds invested in government securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.
Note 11—Subsequent Events
The Company evaluated subsequent events and transactions that occurred up to the date the unaudited condensed financial statements were issued. Based upon this review, except for as noted below, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.
 
18

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
 
On July 25, 2022, the Company entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among the Company, NewAmsterdam Pharma Company B.V., a private company with limited liability (
besloten vennootschap met beperkte aansprakelijkheid
) incorporated under the laws of the Netherlands (“Holdco”), NewAmsterdam Pharma Holding B.V., a private company with limited liability (
besloten vennootschap met beperkte aansprakelijkheid
) incorporated under the laws of the Netherlands (“NewAmsterdam Pharma”) and NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company (“Merger Sub”).
Concurrently with the execution of the Business Combination Agreement, the Company and Holdco entered into subscription agreements with certain investors (collectively, the “PIPE Investors”), pursuant to which, among other things, such PIPE Investors agreed to subscribe for and purchase, and Holdco agreed to issue and sell to such PIPE Investors, 23,460,000 ordinary shares of Holdco, nominal value
EUR 0.12, at $10.00
per share (the “PIPE Shares”), for an aggregate of $234,600,000
in gross proceeds (the “PIPE Financing”). The closing of the PIPE Financing is contingent upon, among other things, the substantially concurrent consummation of the Business Combination and related transactions.
 
19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
References to the “Company,” “Frazier Lifesciences Acquisition Corporation,” “our,” “us” or “we” refer to Frazier Lifesciences Acquisition Corporation. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other U.S. Securities and Exchange Commission (the “SEC”) filings.
Overview
We are a blank check company incorporated on October 7, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this Annual Report on Form
10-K
as our initial business combination. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination. Our sponsor is Frazier Lifesciences Sponsor LLC, a Cayman Islands exempted limited company.
The registration statement for our initial public offering was declared effective on December 8, 2020 (the “Initial Public Offering”). On December 11, 2020, we consummated the Initial Public Offering of 13,800,000 units at $10.00 per unit, generating gross proceeds of $138 million, and incurring offering costs of approximately $8.11 million, inclusive of approximately $4.83 million in deferred underwriting commissions. Each unit consists of one Class A ordinary share and
one-third
of one redeemable warrant. Each whole public warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment.
Simultaneously with the closing of the Initial Public Offering, we consummated the private placement of 501,000 private placement units at a price of $10.00 per private placement unit to the sponsor, generating gross proceeds of approximately $5.01 million. Each private placement unit is identical to the public units sold in the Initial Public Offering, subject to certain limited exceptions.
Upon the closing of the Initial Public Offering and private placement, $138 million of the net proceeds of the Initial Public Offering and certain of the proceeds of the private placement were placed in a trust account, located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee, and will only be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by us meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule
2a-7
of the Investment Company Act, as determined by us, until the earlier of: (i) the completion of a business combination and (ii) the distribution of the assets held in the trust account. Our management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the private placement, although substantially all of the net proceeds are intended to be applied toward consummating a business combination.
If we are unable to complete a business combination within 24 months from the closing of the Initial Public Offering, or December 11, 2022, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a
per-share
price,
 
20

payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay for our income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of our company, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
Liquidity and Going Concern
As of June 30, 2022, we had approximately $615,000 in cash and working capital deficit of approximately $1.1 million.
Our liquidity needs up to June 30, 2022 had been satisfied through a contribution of $25,000 from our sponsor to cover for certain expenses on behalf of us in exchange for the issuance of the founder shares, the loan of approximately $83,000 pursuant to the note issued to our sponsor, and the proceeds from the consummation of the private placement not held in the trust account. We fully repaid the note to our sponsor on December 14, 2020. In addition, in order to finance transaction costs in connection with a business combination, our sponsor or an affiliate of our sponsor, or certain of our officers and directors may, but are not obligated to, provide us working capital loans. To date, there were no amounts outstanding under any working capital loan. On December 30, 2021, upon termination of the term sheet, the Company received a
break-up
fee of $1 million.
Based on the foregoing, our management believes that we will have sufficient working capital and borrowing capacity from our Sponsor or an affiliate of the Sponsor, or certain of the officers and directors to meet our needs through the earlier of the consummation of a Business Combination or one year from this filing. However, in connection with the company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”)
2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” our management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after December 11, 2022. The condensed financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern. Our management intends to complete the Business Combination prior to the liquidation date.
Management continues to evaluate the impact of the
COVID-19
pandemic and has concluded that the specific impact is not readily determinable as of the date of the unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Results of Operations
Our entire activity has been the preparation for our formation and Initial Public Offering, and since our Initial Public Offering, our activity has been limited to the search for a prospective initial Business Combination. We will not be generating any operating revenues until the closing and completion of our initial Business Combination at the earliest.
For the three months ended June 30, 2022, we had net loss of approximately $1.2 million, which consisted of approximately $2.0 million in general and administrative expenses, and $30,000 in administrative expenses-related party, partially offset by approximately $715,000 in change in fair value of derivative warrant liabilities, and approximately $103,000 in interest income from investments held in trust account.
For the three months ended June 30, 2021, we had a net loss of approximately $1.3 million, which consisted of approximately $275,000 in general and administrative expenses, $30,000 in administrative expenses-related party, approximately $1.0 million in change in fair value of derivative warrant liabilities, offset by approximately $7,000 in interest income from investments held in Trust Account.
 
21

For the six months ended June 30, 2022, we had net income of approximately $212,000, which consisted of approximately $2.4 million in change in fair value of derivative warrant liabilities, and approximately $116,000 in interest income from investments held in trust account, offset by approximately $2.3 million in general and administrative expenses, and $60,000 in administrative expenses-related party.
For the six months ended June 30, 2021, we had a net income of approximately $1.5 million, which consisted of approximately $11,000 in interest income from investments held in Trust Account, and approximately $2.0 million in change in fair value of derivative warrant liabilities, offset by approximately $482,000 in general and administrative expenses, and $60,000 in administrative expenses-related party.
Contractual Obligations
Registration and Shareholder Rights
The holders of founder shares, private placement units and warrants that may be issued upon conversion of working capital loans, if any, will be entitled to registration rights (in the case of the founder shares, only after conversion of such shares into Class A ordinary shares) pursuant to a registration and shareholder rights agreement entered into upon consummation of the Initial Public Offering. These holders will be entitled to certain demand and “piggyback” registration and shareholder rights. However, the registration and shareholder rights agreement provides that we will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable
lock-up
period for the securities to be registered. We will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
We granted the underwriters a
45-day
option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 1,800,000 additional units to cover over-allotments, if any, at $10.00 per unit, less underwriting discounts and commissions. The underwriters exercised this option in full on December 11, 2020.
The underwriters were entitled to underwriting discounts of $0.20 per unit, or approximately $2.76 million in the aggregate, paid upon the closing of the Initial Public Offering. An additional fee of $0.35 per unit, or approximately $4.83 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred underwriting commissions will become payable to the underwriters from the amounts held in the trust account solely in the event that we complete a business combination, subject to the terms of the underwriting agreement.
Risks and Uncertainties
Management continues to evaluate the impact of the
COVID-19
pandemic, including new variant strains of the underlying virus, current or anticipated military conflict, including between Russia and Ukraine, terrorism, sanctions or other geopolitical events as well as adverse developments in the economy and capital markets, including rising energy costs, inflation and interest rates, in the United States and globally, on the industry and has concluded that while it is reasonably possible that these events could have a negative effect on our financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Critical Accounting Policies
The preparation of unaudited condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following as our critical accounting policies:
 
22

Class A Ordinary Shares Subject to Possible Redemption
We account for our Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC Topic 480”). Shares of Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Shares of conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, shares of Class A ordinary shares are classified as shareholders’ equity. As part of the private placement, we issued 501,000 Class A ordinary shares to the Sponsor (“Private Placement Shares”). These Private Placement Shares will not be transferable, assignable or salable until 30 days after the completion of our initial business combination, as such are considered
non-redeemable
and presented as permanent equity in our balance sheet. Our Class A ordinary shares features certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ deficit section of the accompanying balance sheets.
Under ASC
480-10-S99,
we have elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, we recognized the accretion from initial book value to redemption amount, which resulted in charges against additional
paid-in
capital (to the extent available) and accumulated deficit.
Derivative Warrant liabilities
We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Subtopic
815-15
“Derivatives and Hedging-Embedded Derivatives” (“ASC Subtopic
815-15”).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
re-assessed
at the end of each reporting period.
The 4,600,000 warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the 167,000 private placement warrants are recognized as derivative liabilities in accordance with Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC Subtopic
815-40”).
Accordingly, we recognize the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to
re-measurement
at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and private placement warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, have been measured based on the listed market price of such warrants.
Net Income (Loss) per Ordinary Shares
We comply with accounting and disclosure requirements of the Financial Accounting Standards Board’s (“FASB”) ASC Topic 260, “Earnings Per Share.” We have two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. This presentation assumes a business combination as the most likely outcome.Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period.
The calculation of diluted net income does not consider the effect of the warrants underlying the units sold in the Initial Public Offering (including the consummation of the over-allotment) and the private placement warrants to purchase an aggregate of 4,767,000 shares of Class A ordinary shares in the calculation of diluted income (loss) per share, because their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the three and six months ended June 30, 2022 and 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.
 
23

Recent Issued Accounting Standards
In June 2022, the FASB issued ASU
2022-03,
ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the condensed financial statements.
Our management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying financial statement.
JOBS Act
The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging
growth companies. As a result, the condensed financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of
non-emerging
growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board (the “PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule
12b-2
of the Exchange Act and are not required to provide the information otherwise required under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2022, as such term is defined in Rules
13a-15(e)
and
15d-15(e)
under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer have concluded that during the period covered by this report, our disclosure controls and procedures were effective as of June 30, 2022.
 
24

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2022 covered by this Quarterly Report on Form
10-Q
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. The material weakness discussed below was remediated during the quarter ended June 30, 2022.
Remediation of a Material Weakness in Internal Control over Financial Reporting
We recognize the importance of the control environment as it sets the overall tone for the Company and is the foundation for all other components of internal control. Consequently, we designed and implemented remediation measures to address the material weakness previously identified in fiscal year 2021 and enhance our internal control over financial reporting. In light of the material weakness, we enhanced our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our condensed financial statements, including providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The foregoing actions, which we believe remediated the material weakness in internal control over financial reporting, were completed as of the date of June 30, 2022.
PART
II-OTHER
INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form
10-K
filed with the SEC on March 25, 2022 and the risks set forth below. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not currently known to us or that we currently deem immaterial may also impair our business or results of operations. You should review the risk factors below for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. For risk factors relating to our business following the Business Combination (referred to in Part I, Note 11 of this Quarterly Report), please refer risk factors disclosed in the section “Risk Factors” in the Registration Statement on Form
F-4,
filed with the SEC on August [4], 2022.
General Risk Factors
The current economic downturn may lead to increased difficulty in completing our initial business combination.
Our ability to consummate our initial business combination may depend, in part, on worldwide economic conditions. In recent months, we have observed increased economic uncertainty in the United States and abroad. Impacts of such economic weakness include:
 
   
falling overall demand for goods and services, leading to reduced profitability;
 
   
reduced credit availability;
 
   
higher borrowing costs;
 
   
reduced liquidity;
 
25

   
volatility in credit, equity and foreign exchange markets; and
 
   
bankruptcies.
These developments could lead to inflation, higher interest rates, and uncertainty about business continuity, which may adversely affect the business of our potential target businesses and create difficulties in obtaining debt or equity financing for our initial business combination, as well as leading to an increase in the number of public stockholders exercising redemption rights in connection therewith.
Recent volatility in capital markets and lower market prices for our securities may affect our ability to obtain financing for our initial business combination through sales of shares of our common stock or issuance of indebtedness.
With uncertainty in the capital markets and other factors, financing for our initial business combination may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may limit the operations and growth of the surviving company of our initial business combination. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to complete our initial business combination.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
 
Exhibit No.
  
Description
  3.1    Amended and Restated Memorandum and Articles of Association.
(1)
  4.1    Warrant Agreement, between the Company and Continental Stock Transfer & Trust Company.
(1)
  4.2    Description of Securities.
(2)
10.1    Investment Management Trust Agreement, between the Company and Continental Stock Transfer & Trust Company.
(1)
10.2    Registration and Stockholder Rights Agreement, by and among the Company, Sponsor, and Holders signatory thereto.
(1)
10.3    Private Placement Warrants Purchase Agreement, between the Company and the Sponsor.
(1)
10.4    Administrative Services Agreement, between the Company and the Sponsor.
(1)
 
26

  10.5    Letter Agreement, by and among the Company, the Sponsor LLC, and each director and officer of the Registrant.
(1)
  14.1    Code of Ethics.
(1)
  31.1*    Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.
  31.2*    Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.
  32.1**    Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350.
  32.2**    Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350.
101.INS*    Inline XBRL Instance Document
101.SCH*    Inline XBRL Taxonomy Extension Schema Document
101.CAL*    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*    Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*    Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*    Inline XBRL Taxonomy Extension Presentation Linkbase Document
104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
 
*
Filed herewith.
**
Furnished herewith.
(1)
Incorporated by reference to the Company’s Current Report on Form
8-K,
filed with the SEC on March 22, 2021.
(2)
Incorporated by reference to the Company’s Registration Statement on Form
S-1,
filed with the SEC on March 1, 2021.
(3)
Incorporated by reference to the Company’s Form
10-K,
filed with the SEC on March 21, 2022.
 
27

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
August 11, 2022    
FRAZIER LIFESCIENCES ACQUISITION CORPORATION
    By:  
/s/ James N. Topper
    Name:   James N. Topper
    Title:  
Chief Executive Officer
(Principal Executive Officer)
 
August 11, 2022     By:  
/s/ David Topper
    Name:   David Topper
    Title:  
Chief Financial Officer
(Principal Financial and Accounting Officer)
 
28
EX-31.1 2 d386684dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, James N. Topper, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of Frazier Lifesciences Acquisition Corporation:

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: August 11, 2022

   

By:

 

/s/ James N. Topper

     

James N. Topper

     

Chief Executive Officer

     

(Principal Executive Officer)

EX-31.2 3 d386684dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Topper, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of Frazier Lifesciences Acquisition Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: August 11, 2022     By:   /s/ David Topper
      David Topper
      Chief Financial Officer
      (Principal Financial and Accounting Officer)
EX-32.1 4 d386684dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Frazier Lifesciences Acquisition Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James N. Topper, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 11, 2022     By:   /s/ James N. Topper
      James N. Topper
      Chief Executive Officer
      (Principal Executive Officer)
EX-32.2 5 d386684dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Frazier Lifesciences Acquisition Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Topper, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 11, 2022

   

By:

 

/s/ David Topper

     

David Topper

     

Chief Financial Officer

     

(Principal Financial and Accounting Officer)

EX-101.SCH 6 flac-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Balance Sheet (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Unaudited Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Unaudited Condensed Statements of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Unaudited Condensed Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Description of Organization, Business Operations and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Initial Public Offering link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Private Placement link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Derivative Warrant Liabilities link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Shareholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Income Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Initial Public Offering - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Private Placement - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption - Summary Of Class A Ordinary Shares Subject To Possible Redemption (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Derivative Warrant Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Shareholders' Deficit - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Fair Value Measurements - Summary Of Quantitative Information Regarding Fair Value Measurements (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 flac-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 flac-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 flac-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 flac-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
6 Months Ended
Jun. 30, 2022
Aug. 11, 2022
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Entity Registrant Name FRAZIER LIFESCIENCES ACQUISITION CORPORATION  
Entity Central Index Key 0001828326  
Document Period End Date Jun. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Incorporation, State or Country Code E9  
Entity File Number 001-39765  
Entity Tax Identification Number 98-1562203  
Entity Address, Address Line One Two Union Square  
Entity Address, Address Line Two 601 Union St., Suite 3200  
Entity Address, City or Town Seattle  
Entity Address, State or Province WA  
Entity Address, Postal Zip Code 98101  
City Area Code 206  
Local Phone Number 621-7200  
Title of 12(b) Security Class A ordinary shares, par value $0.0001 per share  
Trading Symbol FLAC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Units, each consisting of one Class A ordinary share and one-third of a Warrant to acquire one Class A ordinary share [Member]    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one Class A ordinary share and one-third of a Warrant to acquire one Class A ordinary share  
Trading Symbol FLACU  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   14,301,000
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50    
Document Information [Line Items]    
Title of 12(b) Security Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50  
Trading Symbol FLACW  
Security Exchange Name NASDAQ  
Common Class A [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   14,301,000
Common Class B [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   3,450,000
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 615,440 $ 1,226,716
Prepaid expenses 149,722 261,333
Total current assets 765,162 1,488,049
Investments held in Trust Account 138,132,977 138,017,009
Total Assets 138,898,139 139,505,058
Current liabilities:    
Accounts payable 50,698 167,324
Accrued expenses 1,783,891 54,750
Total current liabilities 1,834,589 222,074
Deferred underwriting commissions 4,830,000 4,830,000
Derivative warrant liabilities 381,360 2,812,530
Total liabilities 7,045,949 7,864,604
Commitments and Contingencies
Class A ordinary shares subject to possible redemption, $0.0001 par value; 13,800,000 shares issued and outstanding at redemption value of approximately $10.00 per share at June 30, 2022 and December 31, 2021 138,032,977 138,000,000
Shareholders' Deficit:    
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at June 30, 2022 and December 31, 2021
Additional paid-in capital 0 0
Accumulated deficit (6,181,182) (6,359,941)
Total shareholders' deficit (6,180,787) (6,359,546)
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit 138,898,139 139,505,058
Common Class A [Member]    
Current liabilities:    
Class A ordinary shares subject to possible redemption, $0.0001 par value; 13,800,000 shares issued and outstanding at redemption value of approximately $10.00 per share at June 30, 2022 and December 31, 2021 138,032,977 138,000,000
Shareholders' Deficit:    
Common Stock 50 50
Common Class B [Member]    
Shareholders' Deficit:    
Common Stock $ 345 $ 345
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Balance Sheet (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Dec. 08, 2020
Dec. 07, 2020
Oct. 07, 2020
Temporary equity par or stated value per share $ 0.0001 $ 0.0001      
Temporary equity shares outstanding 13,800,000 13,800,000      
Temporary Equity, Shares Issued 13,800,000 13,800,000      
Temporary equity redemption price per share $ 10 $ 10      
Preferred stock par or stated value per share $ 0.0001 $ 0.0001      
Preferred stock shares authorized 1,000,000 1,000,000      
Preferred stock shares issued 0 0      
Preferred stock shares outstanding 0 0      
Common Class A [Member]          
Temporary equity par or stated value per share $ 0.0001 $ 0.0001      
Temporary equity shares outstanding 13,800,000 13,800,000      
Temporary Equity, Shares Issued 13,800,000 13,800,000      
Common stock par or stated value per share $ 0.0001 $ 0.0001      
Common stock shares authorized 479,000,000 479,000,000      
Common stock shares issued 501,000 501,000      
Common stock shares outstanding 501,000 501,000      
Common Class B [Member]          
Common stock par or stated value per share $ 0.0001 $ 0.0001      
Common stock shares authorized 20,000,000 20,000,000      
Common stock shares issued 3,450,000 3,450,000     2,875,000
Common stock shares outstanding 3,450,000 3,450,000 3,450,000 2,875,000  
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Unaudited Condensed Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
General and administrative expenses $ 1,960,784 $ 275,239 $ 2,275,402 $ 482,480
Administrative expenses—related party 30,000 30,000 60,000 60,000
Loss from operations (1,990,784) (305,239) (2,335,402) (542,480)
Other income (expenses):        
Interest income from investments held in Trust Account 102,847 7,019 115,968 11,466
Change in fair value of derivative warrant liabilities 715,050 (1,001,070) 2,431,170 2,049,810
Net income (loss) (1,172,887) (1,299,290) 211,736 1,518,796
Common Class A [Member]        
Other income (expenses):        
Net income (loss) $ (944,930) $ (1,046,766) $ 170,584 $ 1,223,610
Weighted average number of shares - Basic 14,301,000 14,301,000 14,301,000 14,301,000
Weighted average number of shares - Diluted 14,301,000 14,301,000 14,301,000 14,301,000
Net income (loss) per share - Basic $ (0.07) $ (0.07) $ 0.01 $ 0.09
Net income (loss) per share - Diluted $ (0.07) $ (0.07) $ 0.01 $ 0.09
Common Class B [Member]        
Other income (expenses):        
Net income (loss) $ (227,957) $ (252,524) $ 41,152 $ 295,186
Weighted average number of shares - Basic 3,450,000 3,450,000 3,450,000 3,450,000
Weighted average number of shares - Diluted 3,450,000 3,450,000 3,450,000 3,450,000
Net income (loss) per share - Basic $ (0.07) $ (0.07) $ 0.01 $ 0.09
Net income (loss) per share - Diluted $ (0.07) $ (0.07) $ 0.01 $ 0.09
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Unaudited Condensed Statements of Changes in Shareholders' Equity - USD ($)
Total
Common Class A [Member]
Common Class B [Member]
Ordinary Shares [Member]
Common Class A [Member]
Ordinary Shares [Member]
Common Class B [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020 $ (10,538,073)     $ 50 $ 345 $ 0 $ (10,538,468)
Beginning balance, Shares at Dec. 31, 2020       501,000 3,450,000    
Net income (loss) 2,818,086           2,818,086
Ending balance at Mar. 31, 2021 (7,719,987)     $ 50 $ 345 0 (7,720,382)
Ending balance, Shares at Mar. 31, 2021       501,000 3,450,000    
Beginning balance at Dec. 31, 2020 (10,538,073)     $ 50 $ 345 0 (10,538,468)
Beginning balance, Shares at Dec. 31, 2020       501,000 3,450,000    
Net income (loss) 1,518,796 $ 1,223,610 $ 295,186        
Ending balance at Jun. 30, 2021 (9,019,277)     $ 50 $ 345 0 (9,019,672)
Ending balance, Shares at Jun. 30, 2021       501,000 3,450,000    
Beginning balance at Mar. 31, 2021 (7,719,987)     $ 50 $ 345 0 (7,720,382)
Beginning balance, Shares at Mar. 31, 2021       501,000 3,450,000    
Net income (loss) (1,299,290) (1,046,766) (252,524)       (1,299,290)
Ending balance at Jun. 30, 2021 (9,019,277)     $ 50 $ 345 0 (9,019,672)
Ending balance, Shares at Jun. 30, 2021       501,000 3,450,000    
Beginning balance at Dec. 31, 2021 (6,359,546)     $ 50 $ 345 0 (6,359,941)
Beginning balance, Shares at Dec. 31, 2021       501,000 3,450,000    
Net income (loss) 1,384,623           1,384,623
Ending balance at Mar. 31, 2022 (4,974,923)     $ 50 $ 345 0 (4,975,318)
Ending balance, Shares at Mar. 31, 2022       501,000 3,450,000    
Beginning balance at Dec. 31, 2021 (6,359,546)     $ 50 $ 345 0 (6,359,941)
Beginning balance, Shares at Dec. 31, 2021       501,000 3,450,000    
Net income (loss) 211,736 170,584 41,152        
Ending balance at Jun. 30, 2022 (6,180,787)     $ 50 $ 345 0 (6,181,182)
Ending balance, Shares at Jun. 30, 2022       501,000 3,450,000    
Beginning balance at Mar. 31, 2022 (4,974,923)     $ 50 $ 345 0 (4,975,318)
Beginning balance, Shares at Mar. 31, 2022       501,000 3,450,000    
Increase in redemption value of Class A ordinary shares subject to possible redemption (32,977)           (32,977)
Net income (loss) (1,172,887) $ (944,930) $ (227,957)       (1,172,887)
Ending balance at Jun. 30, 2022 $ (6,180,787)     $ 50 $ 345 $ 0 $ (6,181,182)
Ending balance, Shares at Jun. 30, 2022       501,000 3,450,000    
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Unaudited Condensed Statement of Cash Flows - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Cash Flows from Operating Activities:              
Net income $ (1,172,887) $ 1,384,623 $ (1,299,290) $ 2,818,086 $ 211,736 $ 1,518,796  
Adjustments to reconcile net loss to net cash used in operating activities:              
Interest income from investments held in Trust Account (102,847)   (7,019)   (115,968) (11,466)  
Change in fair value of derivative warrant liabilities (715,050)   1,001,070   (2,431,170) (2,049,810)  
Changes in operating assets and liabilities:              
Prepaid expenses         111,611 85,863  
Accounts payable         (116,626) (97,798)  
Accrued expenses         1,774,141 (22,268)  
Due to related party         0 1,087  
Net cash used in operating activities         (566,276) (575,596)  
Cash Flows from Financing Activities:              
Offering costs paid         (45,000) 0  
Net cash used in financing activities         (45,000) 0  
Net change in cash         (611,276) (575,596)  
Cash—beginning of the period   $ 1,226,716   $ 1,365,094 1,226,716 1,365,094 $ 1,365,094
Cash—end of the period $ 615,440   $ 789,498   $ 615,440 $ 789,498 $ 1,226,716
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Description of Organization, Business Operations and Basis of Presentation
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Organization, Business Operations and Basis of Presentation
Note 1—Description of Organization, Business Operations and Basis of Presentation
Organization and General
Frazier Lifesciences Acquisition Corporation (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 7, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”).
As of June 30, 2022, the Company had not yet commenced operations. All activity for the period from October 7, 2020 (inception) through June 30, 2022 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and after the Initial Public Offering, the search for a target business. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering.
The Company’s Sponsor is Frazier Lifesciences Sponsor LLC, a Cayman Islands limited liability company (“Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on December 8, 2020. On December 11, 2020, the Company consummated its Initial Public Offering of 13,800,000 units (each, a “Unit” and collectively, the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), including 1,800,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $138.0 million, and incurring offering costs of approximately $8.1 million, inclusive of approximately $4.8 million in deferred underwriting commissions (See Note 6).
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 501,000 units (each, a “Private Placement Unit” and collectively, the “Private Placement Units”), at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of approximately $5.0 million (See Note 4).
Upon the closing of the Initial Public Offering and the Private Placement, approximately $138.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule
2a-7
promulgated under the Investment Company Act which will be invested only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding taxes payable on interest earned) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target business or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act.
The Company will provide the holders of the Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned
on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The
per-share
amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). These Public Shares will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC Topic 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the Amended and Restated Memorandum and Articles of Association which was adopted by the Company at the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 5) prior to this Initial Public Offering (the “Initial Shareholders”) agreed to vote their Founder Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares, private placement shares (the “Private Placement Shares”) underlying the Private Placement Units and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor.
Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company.
The Company’s Sponsor, officers or directors agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company’s obligation to allow the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or December 11, 2022, agreement in principle or definitive agreement for an initial Business Combination within 24 months from the closing of the Initial Public Offering (the “Combination Period”), or (B) with respect to any other provisions relating to shareholders’ rights or
pre-initial
Business Combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment.
If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares, at a
per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
In connection with the redemption of 100% of the Company’s outstanding Public Shares for a portion of the funds held in the Trust Account, each holder will receive a full pro rata portion of the amount then in the Trust Account, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes payable (less taxes payable and up to $100,000 of interest to pay dissolution expenses). The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution in the Trust Account will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There can be no guarantee that the Company will be successful in obtaining such waivers from its targeted vendors and service providers.
Risks and Uncertainties
Management continues to evaluate the impact of the
COVID-19
pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these unaudited condensed financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements.
Liquidity and Going Concern
As of June 30, 2022, the Company had approximately $615,000 in its operating bank account, and working capital deficit of approximately $1.1 million.
The Company’s liquidity needs to date have been satisfied through a contribution of $25,000 from Sponsor to cover for certain expenses in exchange for the issuance of the Founder Shares, the loan of approximately $83,000 from the Sponsor under the Note (as defined in Note 5), and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company repaid the Note in full on December 14, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 5). As of June 30, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loan.
Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. However, in connection with the company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”)
2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December 11, 2022. The condensed financial statements do not include any adjustment that might be necessary if the company is unable to continue as a going concern. Management intends to complete the Business Combination prior to the liquidation date.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2—Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022, or any future period.
The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form
10-K
filed by the Company with the SEC on March 25, 2022.
Emerging Growth Company
As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the Jumpstart our Business Startups Act of 2021 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
 
This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.​​​​​​​
Use of Estimates
The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2022 and December 31, 2021.
Investments Held in the Trust Account
The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheets, primarily due to their short-term nature, except for the derivative warrant liabilities (see Note 8).
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Offering Costs Associated with the Initial Public Offering
Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities are expensed as incurred, presented as other expenses in the statement of operations. Offering costs associated with the Public Shares were charged against the carrying value of the Class A ordinary shares subject to redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Derivative Warrant Liabilities
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Subtopic
815-15
“Derivatives and Hedging-Embedded Derivatives” (“ASC Subtopic
815-15”).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
re-assessed
at the end of each reporting period.
The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (as defined in Note 4) are recognized as derivative liabilities in accordance with “Derivatives and Hedging-Contracts in Entity’s Own Equity” (“ASC Subtopic
815-40”).
Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to
re-measurement
at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and have subsequently been measured based on the listed market price of such warrants.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, respectively, outside of the shareholders’ deficit section of the Company’s balance sheets.
Under ASC
480-10-S99,
the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional
paid-in
capital (to the extent available) and accumulated deficit.
Income Taxes
ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) per Ordinary Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. This presentation assumes a business combination as the most likely outcome. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period.
The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the over-allotment) and the Private Placement Warrants to purchase an aggregate of 4,767,000 Class A ordinary shares in the calculation of diluted income per share, because their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the three and six months ended June 30, 2022 and 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.
The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares:
 
 
  
For the Three Months Ended June 30,
 
 
  
2022
 
 
2021
 
 
  
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
Basic and diluted net loss per ordinary share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numerator:
                              
 
Allocation of net loss
  
$
(944,930  
$
(227,957  
$
(1,046,766  
$
(252,524
Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per ordinary share
  
$
(0.07  
$
(0.07  
$
(0.07  
$
(0.07
    
 
 
   
 
 
   
 
 
   
 
 
 
 
 
  
For the Six Months Ended June 30,
 
 
  
2022
 
  
2021
 
 
  
Class A
 
  
Class B
 
  
Class A
 
  
Class B
 
Basic and diluted net income per ordinary share:
                                 
 
Numerator:
                                 
 
Allocation of net income
  
$
170,584    
$
41,152    
$
1,223,610    
$
 
295,186  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Denominator:
                                 
 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net income per ordinary share
   $ 0.01     $ 0.01     $ 0.09     $ 0.09  
    
 
 
   
 
 
   
 
 
   
 
 
 
Recent Issued Accounting Standards
In June 2022, the FASB issued ASU
2022-03,
ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the condensed financial statements.
The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying condensed financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Initial Public Offering
6 Months Ended
Jun. 30, 2022
Initial Public Offering [Abstract]  
Initial Public Offering
Note 3—Initial Public Offering
On December 11, 2020, the Company consummated its Initial Public Offering of 13,800,000 Units, including 1,800,000 Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $138.0 million, and incurring offering costs of approximately $8.1 million, inclusive of approximately $4.8 million in deferred underwriting commissions.
Each Unit consists of one Class A ordinary share and
one-third
of one Public Warrant. Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 7).
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Private Placement
6 Months Ended
Jun. 30, 2022
Private Placement [Abstract]  
Private Placement
Note 4—Private Placement
Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 501,000 Private Placement Units, at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of approximately $5.0 million.
Each Private Placement Unit consists of one Class A ordinary share and
one-third
of one redeemable warrant. Each whole private placement warrant underlying the Private Placement Units (the “Private Placement Warrants”) is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Units will expire worthless. The Private Placement Warrants will be
non-redeemable
except as described below in Note 7 and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units until 30 days after the completion of the initial Business Combination.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions
Note 5—Related Party Transactions
Founder Shares
On October 7, 2020, the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 2,875,000 Class B ordinary shares (the “Founder Shares”). On November 20, 2020, the Sponsor transferred 30,000 Founder Shares to each of the directors other than the Chairman. On December 8, 2020, the Company effected a share
sub-division,
resulting in an increase in the total number of Founder Shares outstanding from 2,875,000 to 3,450,000 shares. All shares and associated amounts have been retroactively restated to reflect the share
sub-division.
The Sponsor agreed to forfeit up to an aggregate of 450,000 Founder Shares to the extent that the option to purchase additional units was not exercised in full by the underwriters so that the Founder Shares would represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters fully exercised the over-allotment option on December 11, 2020; thus, these Founder Shares were no longer subject to forfeiture.
The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share
sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Related Party Loans
On October 7, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is
non-interest
bearing, unsecured and due upon the closing of the Initial Public Offering. The Sponsor paid an aggregate of approximately $83,000 to cover for the Company’s expenses under the Note. On December 14, 2020, the Company fully repaid the Note. The facility is no longer available to be drawn.
In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into private placement units of the post Business Combination entity at a price of $10.00 per unit. The private placement units would be identical to the public units sold, subject to certain limited exceptions. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of June 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans.
Administrative Services Agreement
The Company entered into an agreement that provided that, commencing on the date that the Company’s securities were first listed on the Nasdaq through the earlier of consummation of the initial Business Combination and the liquidation, the Company agreed to pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to the Company. During the three months ended June 30, 2022 and 2021, the Company incurred approximately $30,000 for expenses in connection with the Administrative Services Agreement. During the six months ended June 30, 2022 and 2021, the Company incurred approximately $60,000 for expenses in connection with the Administrative Services Agreement. As of June 30, 2022 and December 31, 2021, we had no amounts payable for such services.
In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any
out-of-pocket
expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, officers or directors, or the Company’s or their affiliates. Any such payments prior to an initial Business Combination will be made from funds held outside the Trust Account.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 6—Commitments and Contingencies
Registration and Shareholder Rights
The holders of the Founder Shares, Private Placement Units, Private Placement Shares, Private Placement Warrants, Class A ordinary shares underlying the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The Company granted the underwriters a
45-day
option from the date of the prospectus relating to the Initial Public Offering to purchase up to 1,800,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. The underwriters fully exercised the over-allotment option on December 11, 2020.
The underwriters were entitled to an underwriting discount of $0.20 per unit, or approximately $2.8 million in the aggregate, which was paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $4.8 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Class A Ordinary Shares Subject To Possible Redemption
6 Months Ended
Jun. 30, 2022
Temporary Equity Disclosure [Abstract]  
Class A Ordinary Shares Subject To Possible Redemption
Note 7—Class A Ordinary Shares Subject To Possible Redemption
The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 479,000,000 ordinary shares with a par value of $0.0001 per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. As of June 30, 2022 and December 31, 2021, there were 14,301,000 Class A ordinary shares issued and outstanding, of which 13,800,000 shares were subject to possible redemption have been classified as temporary equity.
Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table:
 
Gross proceeds
   $  138,000,000  
Less:
  
Fair value of Public Warrants at issuance
     (7,682,000
Offering costs allocated to Class A ordinary shares subject to possible redemption
     (7,653,636
Plus:
  
Accretion on Class A ordinary shares subject to possible redemption amount
     15,335,636  
  
 
 
 
Accretion on Class A ordinary shares subject to possible redemption, December 31, 2021
     138,000,000  
Increase in redemption value of Class A ordinary shares subject to possible redemption
     32,977  
  
 
 
 
Class A ordinary shares subject to possible redemption, June 30, 2022
   $ 138,032,977  
  
 
 
 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative Warrant Liabilities
6 Months Ended
Jun. 30, 2022
Derivative Warrant Liabilities [Abstract]  
Derivative Warrant Liabilities
Note 8—Derivative Warrant Liabilities
As of June 30, 2022 and December 31, 2021, the Company has 4,600,000 and 167,000 Public Warrants and Private Placement Warrants, respectively, outstanding.
Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under certain circumstances). The Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by the Initial Shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the
10-trading
day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the
nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price (and the $10.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price see “Redemption of warrants for cash when the price per class A ordinary share equals or exceeds $18.00” and “Redemption of warrants for Class A ordinary shares when the price per class A ordinary share equals or exceeds $10.00” as described below).
The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except (i) that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (ii) except as described below, the Private Placement Warrants will be
non-redeemable
so long as they are held by the Sponsor or such its permitted transferees and (iii) the Sponsor or its permitted transferees will have the option to exercise the Private Placement Warrants on a cashless basis and have certain registration rights. If the Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by such holders on the same basis as the Public Warrants.
Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00:
Once the warrants become exercisable, the Company may call the outstanding warrants for redemption (except as described herein with respect to the Private Placement Warrants):
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
   
if, and only if, the last reported sales price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share
sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a
30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”).
The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the
30-day
redemption period. If and when the warrants become redeemable by the Company, it may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00:
After the warrants become exercisable, the Company may redeem the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of Class A ordinary shares to be determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares;
 
   
if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted per share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and
 
   
if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), then the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder’s ability to cashless exercise its warrants) as the outstanding Public Warrants as described above.
The “fair market value” of Class A ordinary shares for the above purpose shall mean the volume weighted average price of Class A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment).
In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholders' Deficit
6 Months Ended
Jun. 30, 2022
Stockholders' Equity Note [Abstract]  
Shareholders' Deficit
Note 9—Shareholders’ Deficit
Preference Shares
- The Company is authorized to issue
1,000,000
preference shares with a par value of $
0.0001
per share. At June 30, 2022 and December 31, 2021, there were
no
preference shares issued or outstanding.
Class
 A Ordinary Shares
- The Company is authorized to issue
479,000,000
Class A ordinary shares with a par value of $
0.0001
per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were
14,301,000
Class A ordinary shares issued and outstanding, of which
13,800,000
shares were subject to possible redemption have been classified as temporary equity (see Note 7).
Class
 B Ordinary Shares
- The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. On October 7, 2020, the Company issued 2,875,000 Class B ordinary shares. On December 8, 2020, the Company effected a share
sub-division,
resulting in an increase in the total number of Class B ordinary shares outstanding from 2,875,000 to 3,450,000 shares. All shares and associated amounts have been retroactively restated to reflect the share
sub-division.
Of the 3,450,000 Class B ordinary shares outstanding, up to 450,000 shares were subject to forfeiture, to the Company by the Initial Shareholders for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the Initial Shareholders would collectively own 20% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering (excluding the Private Placement Shares and assuming the initial shareholders do not purchase any units in the Initial Public Offering). The underwriters fully exercised the over-allotment option on December 11, 2020; thus, these 450,000 Class B ordinary shares were no longer subject to forfeiture. At June 30, 2022 and December 31, 2021, there were
3,450,000
Class B ordinary shares issued and outstanding period. Class A and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the appointment of directors. Holders of the Public Shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason. The provisions of the Amended and Restated Memorandum and Articles of Association governing the appointment or removal of directors prior to the initial Business Combination may only be amended by a special resolution passed by holders representing at least
two-thirds
of the issued and outstanding Class B ordinary shares.
The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of (i) the total number of ordinary shares (excluding the Private Placement Shares) issued and outstanding upon the consummation of the Initial Public Offering, plus (ii) the sum of the total number of Class A ordinary shares issued
or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination (net of any redemptions of Class A ordinary shares by Public Shareholders), excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Units issued to the Sponsor, members of the founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 10—Fair Value Measurements
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.
June 30, 2022
 
Description
  
Quoted Prices
in
Active Markets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Other
Unobservable
Inputs
(Level 3)
 
Assets:
                          
Investments held in Trust Account
   $ 138,132,977      $ —        $ —    
Liabilities:
                          
Derivative warrant liabilities
   $      $ 381,360      $ —    
December 31, 2021
 
Description
  
Quoted Prices
in
Active Markets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Other
Unobservable
Inputs
(Level 3)
 
Assets:
                          
Investments held in Trust Account
   $ 138,017,009      $ —        $ —    
Liabilities:
                          
Derivative warrant liabilities
   $ 2,714,000      $ 98,530      $ —    
Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants of $7,084,000 transferred from a Level 3 measurement to a Level 1 fair value measurement in January 2021, when the Public Warrants were separately listed and traded. The estimated fair value of the Private Warrants of $257,180 was transferred from a Level 3 measurement to a Level 2 fair value measurement in January 2021, as the transfer of Private Placement Warrants to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant.
The estimated fair value of Public Warrants was transferred from a Level 1 measurement to a Level 2 measurement due to lack of trading activity as of June 30, 2022. There were no other transfers to/from Levels 1, 2, and 3 during the six months ended June 30, 2022.
For the three and six months ended June 30, 2022, the Company recognized a gain in the unaudited condensed statements of operations resulting from a decrease in fair value of the derivative warrant liabilities of approximately $
715,000
and $
2.4
 million, respectively, presented as change in fair value of derivative warrant liabilities in the accompanying unaudited condensed statements of operations.
Level 1 instruments include investments in mutual funds invested in government securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events
Note 11—Subsequent Events
The Company evaluated subsequent events and transactions that occurred up to the date the unaudited condensed financial statements were issued. Based upon this review, except for as noted below, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.
 
On July 25, 2022, the Company entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among the Company, NewAmsterdam Pharma Company B.V., a private company with limited liability (
besloten vennootschap met beperkte aansprakelijkheid
) incorporated under the laws of the Netherlands (“Holdco”), NewAmsterdam Pharma Holding B.V., a private company with limited liability (
besloten vennootschap met beperkte aansprakelijkheid
) incorporated under the laws of the Netherlands (“NewAmsterdam Pharma”) and NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company (“Merger Sub”).
Concurrently with the execution of the Business Combination Agreement, the Company and Holdco entered into subscription agreements with certain investors (collectively, the “PIPE Investors”), pursuant to which, among other things, such PIPE Investors agreed to subscribe for and purchase, and Holdco agreed to issue and sell to such PIPE Investors, 23,460,000 ordinary shares of Holdco, nominal value
EUR 0.12, at $10.00
per share (the “PIPE Shares”), for an aggregate of $234,600,000
in gross proceeds (the “PIPE Financing”). The closing of the PIPE Financing is contingent upon, among other things, the substantially concurrent consummation of the Business Combination and related transactions.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022, or any future period.
The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form
10-K
filed by the Company with the SEC on March 25, 2022.
Emerging Growth Company
Emerging Growth Company
As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the Jumpstart our Business Startups Act of 2021 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.​​​​​​​
Use of Estimates
Use of Estimates
The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2022 and December 31, 2021.
Investments Held in the Trust Account
Investments Held in the Trust Account
The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheets, primarily due to their short-term nature, except for the derivative warrant liabilities (see Note 8).
Fair Value Measurements
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Offering Costs Associated with the Initial Public Offering
Offering Costs Associated with the Initial Public Offering
Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities are expensed as incurred, presented as other expenses in the statement of operations. Offering costs associated with the Public Shares were charged against the carrying value of the Class A ordinary shares subject to redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Derivative Warrant Liabilities
Derivative Warrant Liabilities
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Subtopic
815-15
“Derivatives and Hedging-Embedded Derivatives” (“ASC Subtopic
815-15”).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
re-assessed
at the end of each reporting period.
The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (as defined in Note 4) are recognized as derivative liabilities in accordance with “Derivatives and Hedging-Contracts in Entity’s Own Equity” (“ASC Subtopic
815-40”).
Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to
re-measurement
at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and have subsequently been measured based on the listed market price of such warrants.
Class A Ordinary Shares Subject to Possible Redemption
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, respectively, outside of the shareholders’ deficit section of the Company’s balance sheets.
Under ASC
480-10-S99,
the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional
paid-in
capital (to the extent available) and accumulated deficit.
Income Taxes
Income Taxes
ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) per Ordinary Share
Net Income (Loss) per Ordinary Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. This presentation assumes a business combination as the most likely outcome. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period.
The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the over-allotment) and the Private Placement Warrants to purchase an aggregate of 4,767,000 Class A ordinary shares in the calculation of diluted income per share, because their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the three and six months ended June 30, 2022 and 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.
The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares:
 
 
  
For the Three Months Ended June 30,
 
 
  
2022
 
 
2021
 
 
  
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
Basic and diluted net loss per ordinary share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numerator:
                              
 
Allocation of net loss
  
$
(944,930  
$
(227,957  
$
(1,046,766  
$
(252,524
Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per ordinary share
  
$
(0.07  
$
(0.07  
$
(0.07  
$
(0.07
    
 
 
   
 
 
   
 
 
   
 
 
 
 
 
  
For the Six Months Ended June 30,
 
 
  
2022
 
  
2021
 
 
  
Class A
 
  
Class B
 
  
Class A
 
  
Class B
 
Basic and diluted net income per ordinary share:
                                 
 
Numerator:
                                 
 
Allocation of net income
  
$
170,584    
$
41,152    
$
1,223,610    
$
 
295,186  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Denominator:
                                 
 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net income per ordinary share
   $ 0.01     $ 0.01     $ 0.09     $ 0.09  
    
 
 
   
 
 
   
 
 
   
 
 
 
Recent Issued Accounting Standards
Recent Issued Accounting Standards
In June 2022, the FASB issued ASU
2022-03,
ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the condensed financial statements.
The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying condensed financial statements.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Basic and Diluted Net Income Per Share
The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares:
 
 
  
For the Three Months Ended June 30,
 
 
  
2022
 
 
2021
 
 
  
Class A
 
 
Class B
 
 
Class A
 
 
Class B
 
Basic and diluted net loss per ordinary share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numerator:
                              
 
Allocation of net loss
  
$
(944,930  
$
(227,957  
$
(1,046,766  
$
(252,524
Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net loss per ordinary share
  
$
(0.07  
$
(0.07  
$
(0.07  
$
(0.07
    
 
 
   
 
 
   
 
 
   
 
 
 
 
 
  
For the Six Months Ended June 30,
 
 
  
2022
 
  
2021
 
 
  
Class A
 
  
Class B
 
  
Class A
 
  
Class B
 
Basic and diluted net income per ordinary share:
                                 
 
Numerator:
                                 
 
Allocation of net income
  
$
170,584    
$
41,152    
$
1,223,610    
$
 
295,186  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Denominator:
                                 
 
Basic and diluted weighted average ordinary shares outstanding
     14,301,000       3,450,000       14,301,000       3,450,000  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted net income per ordinary share
   $ 0.01     $ 0.01     $ 0.09     $ 0.09  
    
 
 
   
 
 
   
 
 
   
 
 
 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Class A Ordinary Shares Subject To Possible Redemption (Tables)
6 Months Ended
Jun. 30, 2022
Temporary Equity Disclosure [Abstract]  
Summary Of Class A Ordinary Shares Subject To Possible Redemption
Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table:
 
Gross proceeds
   $  138,000,000  
Less:
  
Fair value of Public Warrants at issuance
     (7,682,000
Offering costs allocated to Class A ordinary shares subject to possible redemption
     (7,653,636
Plus:
  
Accretion on Class A ordinary shares subject to possible redemption amount
     15,335,636  
  
 
 
 
Accretion on Class A ordinary shares subject to possible redemption, December 31, 2021
     138,000,000  
Increase in redemption value of Class A ordinary shares subject to possible redemption
     32,977  
  
 
 
 
Class A ordinary shares subject to possible redemption, June 30, 2022
   $ 138,032,977  
  
 
 
 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of quantitative information regarding fair value measurements
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.
June 30, 2022
 
Description
  
Quoted Prices
in
Active Markets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Other
Unobservable
Inputs
(Level 3)
 
Assets:
                          
Investments held in Trust Account
   $ 138,132,977      $ —        $ —    
Liabilities:
                          
Derivative warrant liabilities
   $      $ 381,360      $ —    
December 31, 2021
 
Description
  
Quoted Prices
in
Active Markets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Other
Unobservable
Inputs
(Level 3)
 
Assets:
                          
Investments held in Trust Account
   $ 138,017,009      $ —        $ —    
Liabilities:
                          
Derivative warrant liabilities
   $ 2,714,000      $ 98,530      $ —    
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail) - USD ($)
6 Months Ended 12 Months Ended
Dec. 11, 2020
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Sale of stock issue price per share $ 10      
Proceeds from initial public offer $ 138,000,000      
Adjustments to additional paid in capital stock issuance costs 8,100,000      
Deferred underwriting commissions $ 4,800,000 $ 4,830,000   $ 4,830,000
Proceeds from private placement   5,000,000    
Payment to acquire restricted investments   $ 138,000,000    
Restricted investment value per share   $ 10    
Term of restricted investments   185 days 185 days  
Temporary equity redemption price per share   $ 10   $ 10
Minimum net worth necessary to carry out business combination   $ 5,000,001    
Percentage of public shares to be redeemed in case business combination is not consummated   100.00%    
Period within which business combination shall be consummated from the date of initial public offer   24 months    
Expenses payable on liquidation   $ 100,000    
Minimum per share amount to be maintained in the trust account   $ 10    
Cash at bank   $ 615,440   $ 1,226,716
Net working capital   1,100,000    
Proceeds from related party debt   83,000    
Stock issued during period, value, issued for services   $ 25,000    
Minimum [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Fair value of net assets of the acquire as a percentage of assets in the trust account   80.00%    
Equity method investment ownership percentage   50.00%    
IPO [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Proceeds from initial public offer       $ 138,000,000
Common Class A [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Percentage of shares eligible to be transferred without any restriction   15.00%    
Common Class A [Member] | IPO [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Stock issued during the period shares 13,800,000      
Common Class A [Member] | Over-Allotment Option [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Stock issued during the period shares 1,800,000      
Class A Common Stock And One Third Of One Redeemable Warrant | Private Placement [Member]        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Stock issued during the period shares   501,000    
Sale of stock issue price per share   $ 10    
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Accounting Policies [Line Items]      
Term of restricted investments 185 days 185 days  
Cash insured with federal depository insurance corporation $ 250,000    
Temporary equity shares outstanding 13,800,000   13,800,000
Unrecognized tax benefits $ 0   $ 0
Accrued interest and penalties on unrecognized tax benefits 0   0
Cash equivalents in its operating account $ 0   $ 0
Class A Common Stock Subject to Possible Redemption [Member]      
Accounting Policies [Line Items]      
Temporary equity shares outstanding 13,800,000   13,800,000
Warrant [Member]      
Accounting Policies [Line Items]      
Antidilutive securities excluded from the computation of earnings per share 4,767,000    
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Income Per Share (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator:            
Allocation of net income (loss) $ (1,172,887) $ 1,384,623 $ (1,299,290) $ 2,818,086 $ 211,736 $ 1,518,796
Common Class A [Member]            
Numerator:            
Allocation of net income (loss) $ (944,930)   $ (1,046,766)   $ 170,584 $ 1,223,610
Denominator:            
Weighted average number of shares - Diluted 14,301,000   14,301,000   14,301,000 14,301,000
Weighted average number of shares - Basic 14,301,000   14,301,000   14,301,000 14,301,000
Net income (loss) per share - Basic $ (0.07)   $ (0.07)   $ 0.01 $ 0.09
Net income (loss) per share - Diluted $ (0.07)   $ (0.07)   $ 0.01 $ 0.09
Common Class B [Member]            
Numerator:            
Allocation of net income (loss) $ (227,957)   $ (252,524)   $ 41,152 $ 295,186
Denominator:            
Weighted average number of shares - Diluted 3,450,000   3,450,000   3,450,000 3,450,000
Weighted average number of shares - Basic 3,450,000   3,450,000   3,450,000 3,450,000
Net income (loss) per share - Basic $ (0.07)   $ (0.07)   $ 0.01 $ 0.09
Net income (loss) per share - Diluted $ (0.07)   $ (0.07)   $ 0.01 $ 0.09
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Initial Public Offering - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 11, 2020
Dec. 31, 2021
Jun. 30, 2022
Initial Public Offering [Line Items]      
Sale of stock issue price per share $ 10    
Proceeds from initial public offer $ 138,000,000    
Adjustments to additional paid in capital stock issuance costs 8,100,000    
Deferred underwriting commissions $ 4,800,000 $ 4,830,000 $ 4,830,000
Class of warrant or right, exercise price of warrants or rights     $ 11.5
IPO [Member]      
Initial Public Offering [Line Items]      
Proceeds from initial public offer   $ 138,000,000  
Common Class A [Member]      
Initial Public Offering [Line Items]      
Class of warrant or right, exercise price of warrants or rights $ 11.5   $ 11.5
Common Class A [Member] | IPO [Member]      
Initial Public Offering [Line Items]      
Stock issued during the period shares 13,800,000    
Common Class A [Member] | Over-Allotment Option [Member]      
Initial Public Offering [Line Items]      
Stock issued during the period shares 1,800,000    
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Private Placement - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2022
Dec. 11, 2020
Private Placement [Line Items]    
Sale of stock issue price per share   $ 10
Proceeds from private placement $ 5.0  
Class of warrant or right, exercise price of warrants or rights $ 11.5  
Class A Common Stock and One Third of One Redeemable Warrant [Member] | Private Placement [Member]    
Private Placement [Line Items]    
Stock issued during the period shares 501,000  
Sale of stock issue price per share $ 10  
Common Class A [Member]    
Private Placement [Line Items]    
Class of warrant or right, exercise price of warrants or rights $ 11.5 $ 11.5
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Oct. 07, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 08, 2020
Dec. 07, 2020
Nov. 20, 2020
Payments of stock issuance costs       $ 45,000 $ 0        
Proceeds from related party debt       83,000          
Agreed amount to repay for administrative services   $ 10,000   10,000          
Administrative expenses—related party   30,000 $ 30,000 60,000 60,000        
Administration And Support Services [Member]                  
Administrative expenses—related party   30,000 $ 30,000 60,000 $ 60,000        
Accounts Payable, Related Parties, Current   0   0   $ 0      
Related Party Loan [Member]                  
Line of credit facility, maximum borrowing capacity $ 300,000                
Proceeds from related party debt $ 83,000                
Working Capital Loan [Member]                  
Share Price $ 10                
Convertible debt $ 1,500,000                
Long-term debt, gross   $ 0   $ 0   $ 0      
Founder Shares [Member]                  
Payments of stock issuance costs $ 25,000                
Number of shares transferred                 30,000
Common Class A [Member]                  
Common stock shares outstanding   501,000   501,000   501,000      
Share Price   $ 9.2   $ 9.2          
Common Class A [Member] | Minimum [Member]                  
Share Price             $ 12    
Common Class B [Member]                  
Common stock shares outstanding   3,450,000   3,450,000   3,450,000 3,450,000 2,875,000  
Number of shares forfeited             450,000    
Percent of founder shares to issued and outstanding shares             20.00%    
Common Class B [Member] | Founder Shares [Member]                  
Stock issued during the period shares 2,875,000                
Common stock shares outstanding             3,450,000 2,875,000  
Number of shares forfeited             450,000    
Percent of founder shares to issued and outstanding shares             20.00%    
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
Dec. 11, 2020
Jun. 30, 2022
Loss Contingencies [Line Items]    
Underwriting discount per unit   $ 0.2
Underwriting discount value   $ 2.8
Deferred underwriting commissions per unit   $ 0.35
Deferred underwriting commissions value   $ 4.8
Over-Allotment Option [Member] | Common Class A [Member]    
Loss Contingencies [Line Items]    
Stock issued during the period shares 1,800,000  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Class A Ordinary Shares Subject To Possible Redemption - Additional Information (Detail) - $ / shares
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Redeemable Noncontrolling Interest [Line Items]    
Temporary Equity, Shares Outstanding 13,800,000 13,800,000
Temporary Equity, Shares Issued 13,800,000 13,800,000
Common Class A [Member]    
Redeemable Noncontrolling Interest [Line Items]    
Common stock shares authorized 479,000,000 479,000,000
Common Stock, No Par Value $ 0.0001  
Common Stock, Voting Rights one vote  
Temporary Equity, Shares Outstanding 13,800,000 13,800,000
Temporary Equity Shares Subject To Possible Redemption 14,301,000  
Temporary Equity, Shares Issued 13,800,000 13,800,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Class A Ordinary Shares Subject To Possible Redemption - Summary Of Class A Ordinary Shares Subject To Possible Redemption (Detail) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 11, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Temporary Equity [Line Items]            
Gross proceeds $ 138,000,000          
Proceeds allocated to public warrants   $ (715,050) $ 1,001,070 $ (2,431,170) $ (2,049,810)  
Class A ordinary share subject to possible redemption   138,032,977   138,032,977   $ 138,000,000
IPO [Member]            
Temporary Equity [Line Items]            
Gross proceeds           138,000,000
Proceeds allocated to public warrants           (7,682,000)
Common Class A [Member]            
Temporary Equity [Line Items]            
Class A ordinary share issuance costs           (7,653,636)
Accretion of carrying value to redemption value       32,977   15,335,636
Class A ordinary share subject to possible redemption   $ 138,032,977   $ 138,032,977   $ 138,000,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative Warrant Liabilities - Additional Information (Detail) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Dec. 11, 2020
Derivative Warrant Liabilities [Line Items]      
Exercise Price of Warrants or Rights $ 11.5    
Warrants and Rights Outstanding, Term 5 years    
Percent of gross proceeds from such issuances to total equity proceeds 60.00%    
Number of Securities Called by Each Warrant or Right 0.361    
Share Trigger Price One [Member]      
Derivative Warrant Liabilities [Line Items]      
Share Price $ 9.2    
Percent of exercise price of the warrants adjusted to share price 115.00%    
Share Trigger Price Two [Member]      
Derivative Warrant Liabilities [Line Items]      
Exercise Price of Warrants or Rights $ 0.01    
Share Price $ 18    
Percent of exercise price of the warrants adjusted to share price 180.00%    
Share Trigger Price Three [Member]      
Derivative Warrant Liabilities [Line Items]      
Exercise Price of Warrants or Rights $ 0.1    
Share Price 10    
Common Class A [Member]      
Derivative Warrant Liabilities [Line Items]      
Exercise Price of Warrants or Rights 11.5   $ 11.5
Share Price $ 9.2    
Public Warrants [Member]      
Derivative Warrant Liabilities [Line Items]      
Class of Warrant or Right, Outstanding 4,600,000    
Private Placement Warrants [Member]      
Derivative Warrant Liabilities [Line Items]      
Class of Warrant or Right, Outstanding   167,000  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholders' Deficit - Additional Information (Detail) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Dec. 08, 2020
Dec. 07, 2020
Oct. 07, 2020
Class of Stock [Line Items]          
Preferred stock shares authorized 1,000,000 1,000,000      
Preferred stock par or stated value per share $ 0.0001 $ 0.0001      
Preferred stock shares issued 0 0      
Preferred stock shares outstanding 0 0      
Temporary equity par or stated value per share $ 0.0001 $ 0.0001      
Temporary equity shares outstanding 13,800,000 13,800,000      
Percent of shares convertible 20.00%        
Common Class A [Member]          
Class of Stock [Line Items]          
Temporary Equity, Shares Authorized 479,000,000 479,000,000      
Temporary equity par or stated value per share $ 0.0001 $ 0.0001      
Common stock shares issued including temporary equity 14,301,000 14,301,000      
Common stock shares outstanding including temporary equity 14,301,000 14,301,000      
Temporary equity shares outstanding 13,800,000 13,800,000      
Common stock shares authorized 479,000,000 479,000,000      
Common stock par or stated value per share $ 0.0001 $ 0.0001      
Common stock shares issued 501,000 501,000      
Common stock shares outstanding 501,000 501,000      
Common Class B [Member]          
Class of Stock [Line Items]          
Common stock shares authorized 20,000,000 20,000,000      
Common stock par or stated value per share $ 0.0001 $ 0.0001      
Common stock shares issued 3,450,000 3,450,000     2,875,000
Common stock shares outstanding 3,450,000 3,450,000 3,450,000 2,875,000  
Number of shares forfeited     450,000    
Percent of founder shares to issued and outstanding shares     20.00%    
Number of shares no longer subject to forfeiture 450,000 450,000      
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Summary Of Quantitative Information Regarding Fair Value Measurements (Detail) - Fair Value, Recurring [Member] - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Inputs, Level 1 [Member] | Investments Held in Trust Account [Member]    
Assets:    
Cash held in Trust Account $ 138,132,977 $ 138,017,009
Fair Value, Inputs, Level 1 [Member] | Derivative Warrant Liabilities [Member]    
Liabilities:    
Derivative warrant liabilities 0 2,714,000
Fair Value, Inputs, Level 2 [Member] | Investments Held in Trust Account [Member]    
Assets:    
Cash held in Trust Account 0 0
Fair Value, Inputs, Level 2 [Member] | Derivative Warrant Liabilities [Member]    
Liabilities:    
Derivative warrant liabilities 381,360 98,530
Fair Value, Inputs, Level 3 [Member] | Investments Held in Trust Account [Member]    
Assets:    
Cash held in Trust Account 0 0
Fair Value, Inputs, Level 3 [Member] | Derivative Warrant Liabilities [Member]    
Liabilities:    
Derivative warrant liabilities $ 0 $ 0
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of public warrants $ 7,084,000   $ 7,084,000  
Fair value of private warrants 257,180   257,180  
Change in fair value of derivative warrant liabilities $ 715,050 $ (1,001,070) $ 2,431,170 $ 2,049,810
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events - Additional Information (Detail) - Jul. 25, 2022 - Subsequent Event [Member] - PIPE Shares [Member]
USD ($)
shares
€ / shares
$ / shares
Subsequent Event [Line Items]      
Stock Issued During Period, Shares, New Issues | shares 23,460,000    
Shares Issued, Price Per Share | (per share)   € 0.12 $ 10
Proceeds from Issuance of Common Stock | $ $ 234,600,000    
XML 46 d386684d10q_htm.xml IDEA: XBRL DOCUMENT 0001828326 2021-12-31 0001828326 2022-06-30 0001828326 2021-01-01 2021-06-30 0001828326 2022-01-01 2022-06-30 0001828326 2021-04-01 2021-06-30 0001828326 2022-04-01 2022-06-30 0001828326 2021-01-01 2021-03-31 0001828326 2022-01-01 2022-03-31 0001828326 2020-12-11 0001828326 2020-12-11 2020-12-11 0001828326 2020-12-31 0001828326 2021-06-30 0001828326 2021-03-31 0001828326 2022-03-31 0001828326 us-gaap:CommonClassBMember 2022-06-30 0001828326 us-gaap:CommonClassAMember 2022-06-30 0001828326 flac:ClassACommonStockSubjectToPossibleRedemptionMember 2022-06-30 0001828326 flac:ClassACommonStockAndOneThirdOfOneRedeemableWarrantMember us-gaap:PrivatePlacementMember 2022-06-30 0001828326 srt:MinimumMember 2022-06-30 0001828326 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember flac:InvestmentsHeldInTrustAccountMember 2022-06-30 0001828326 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember flac:InvestmentsHeldInTrustAccountMember 2022-06-30 0001828326 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember flac:InvestmentsHeldInTrustAccountMember 2022-06-30 0001828326 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember flac:DerivativeWarrantLiabilitiesMember 2022-06-30 0001828326 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember flac:DerivativeWarrantLiabilitiesMember 2022-06-30 0001828326 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember flac:DerivativeWarrantLiabilitiesMember 2022-06-30 0001828326 flac:PublicWarrantsMember 2022-06-30 0001828326 flac:ShareTriggerPriceThreeMember 2022-06-30 0001828326 flac:ShareTriggerPriceTwoMember 2022-06-30 0001828326 flac:ShareTriggerPriceOneMember 2022-06-30 0001828326 flac:WorkingCapitalLoanMember 2022-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2022-06-30 0001828326 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2021-04-01 2021-06-30 0001828326 us-gaap:CommonClassAMember 2021-04-01 2021-06-30 0001828326 us-gaap:CommonClassBMember 2021-04-01 2021-06-30 0001828326 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2022-04-01 2022-06-30 0001828326 us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001828326 us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001828326 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001828326 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001828326 flac:ClassACommonStockAndOneThirdOfOneRedeemableWarrantMember us-gaap:PrivatePlacementMember 2022-01-01 2022-06-30 0001828326 flac:AdministrationAndSupportServicesMember 2022-01-01 2022-06-30 0001828326 us-gaap:CapitalUnitsMember 2022-01-01 2022-06-30 0001828326 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001828326 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001828326 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001828326 us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2020-12-11 2020-12-11 0001828326 us-gaap:CommonClassAMember us-gaap:IPOMember 2020-12-11 2020-12-11 0001828326 us-gaap:CommonClassAMember 2020-12-11 0001828326 flac:FounderSharesMember 2020-10-07 2020-10-07 0001828326 us-gaap:CommonClassBMember flac:FounderSharesMember 2020-10-07 2020-10-07 0001828326 flac:RelatedPartyLoanMember 2020-10-07 2020-10-07 0001828326 flac:FounderSharesMember 2020-11-20 0001828326 us-gaap:CommonClassBMember flac:FounderSharesMember 2020-12-07 0001828326 us-gaap:CommonClassBMember 2020-12-07 0001828326 us-gaap:CommonClassBMember flac:FounderSharesMember 2020-12-08 0001828326 srt:MinimumMember us-gaap:CommonClassAMember 2020-12-08 0001828326 us-gaap:CommonClassBMember 2020-12-08 0001828326 flac:WorkingCapitalLoanMember 2020-10-07 0001828326 flac:RelatedPartyLoanMember 2020-10-07 0001828326 us-gaap:CommonClassBMember 2020-10-07 0001828326 us-gaap:CommonClassBMember 2021-12-31 0001828326 us-gaap:CommonClassAMember 2021-12-31 0001828326 flac:ClassACommonStockSubjectToPossibleRedemptionMember 2021-12-31 0001828326 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember flac:InvestmentsHeldInTrustAccountMember 2021-12-31 0001828326 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember flac:InvestmentsHeldInTrustAccountMember 2021-12-31 0001828326 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember flac:InvestmentsHeldInTrustAccountMember 2021-12-31 0001828326 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember flac:DerivativeWarrantLiabilitiesMember 2021-12-31 0001828326 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember flac:DerivativeWarrantLiabilitiesMember 2021-12-31 0001828326 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember flac:DerivativeWarrantLiabilitiesMember 2021-12-31 0001828326 flac:PrivatePlacementWarrantsMember 2021-12-31 0001828326 flac:WorkingCapitalLoanMember 2021-12-31 0001828326 flac:AdministrationAndSupportServicesMember 2021-12-31 0001828326 flac:AdministrationAndSupportServicesMember 2021-01-01 2021-06-30 0001828326 us-gaap:CommonClassAMember 2021-01-01 2021-06-30 0001828326 us-gaap:CommonClassBMember 2021-01-01 2021-06-30 0001828326 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001828326 us-gaap:IPOMember 2021-01-01 2021-12-31 0001828326 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001828326 flac:PipeSharesMember us-gaap:SubsequentEventMember 2022-07-25 2022-07-25 0001828326 flac:PipeSharesMember us-gaap:SubsequentEventMember 2022-07-25 0001828326 us-gaap:CapitalUnitsMember 2022-08-11 0001828326 us-gaap:CommonClassAMember 2022-08-11 0001828326 us-gaap:CommonClassBMember 2022-08-11 0001828326 us-gaap:RetainedEarningsMember 2021-06-30 0001828326 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001828326 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001828326 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-30 0001828326 us-gaap:RetainedEarningsMember 2022-06-30 0001828326 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001828326 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001828326 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001828326 us-gaap:RetainedEarningsMember 2020-12-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001828326 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001828326 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001828326 us-gaap:RetainedEarningsMember 2021-03-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001828326 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-03-31 0001828326 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-31 0001828326 us-gaap:RetainedEarningsMember 2021-12-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001828326 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001828326 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001828326 us-gaap:RetainedEarningsMember 2022-03-31 0001828326 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001828326 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001828326 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 iso4217:USD shares utr:Day pure utr:Month utr:Year iso4217:USD shares iso4217:EUR shares false 0001828326 Q2 --12-31 WA 10-Q true 2022-06-30 2022 false 001-39765 FRAZIER LIFESCIENCES ACQUISITION CORPORATION E9 98-1562203 Two Union Square 601 Union St., Suite 3200 Seattle 98101 206 621-7200 Units, each consisting of one Class A ordinary share and one-third of a Warrant to acquire one Class A ordinary share FLACU NASDAQ Class A ordinary shares, par value $0.0001 per share FLAC NASDAQ Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 FLACW NASDAQ Yes Yes Non-accelerated Filer true true false true 14301000 14301000 3450000 615440 1226716 149722 261333 765162 1488049 138132977 138017009 138898139 139505058 50698 167324 1783891 54750 1834589 222074 4830000 4830000 381360 2812530 7045949 7864604 0.0001 0.0001 13800000 13800000 13800000 13800000 10 10 138032977 138000000 0.0001 0.0001 1000000 1000000 0 0 0 0 0.0001 0.0001 0.0001 479000000 479000000 501000 501000 501000 501000 13800000 13800000 13800000 50 50 0.0001 0.0001 20000000 20000000 3450000 3450000 3450000 3450000 345 345 0 0 -6181182 -6359941 -6180787 -6359546 138898139 139505058 1960784 275239 2275402 482480 30000 30000 60000 60000 -1990784 -305239 -2335402 -542480 102847 7019 115968 11466 -715050 1001070 -2431170 -2049810 -1172887 -1299290 211736 1518796 14301000 14301000 14301000 14301000 14301000 14301000 14301000 14301000 -0.07 -0.07 -0.07 -0.07 0.01 0.01 0.09 0.09 3450000 3450000 3450000 3450000 3450000 3450000 3450000 3450000 -0.07 -0.07 -0.07 -0.07 0.01 0.01 0.09 0.09 501000 50 3450000 345 0 -6359941 -6359546 1384623 1384623 501000 50 3450000 345 0 -4975318 -4974923 32977 32977 -1172887 -1172887 501000 50 3450000 345 0 -6181182 -6180787 501000 50 3450000 345 0 -10538468 -10538073 2818086 2818086 501000 50 3450000 345 0 -7720382 -7719987 -1299290 -1299290 501000 50 3450000 345 0 -9019672 -9019277 211736 1518796 115968 11466 -2431170 -2049810 -111611 -85863 -116626 -97798 1774141 -22268 0 1087 -566276 -575596 45000 0 -45000 0 -611276 -575596 1226716 1365094 615440 789498 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 1—Description of Organization, Business Operations and Basis of Presentation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Organization and General </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frazier Lifesciences Acquisition Corporation (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 7, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2022, the Company had not yet commenced operations. All activity for the period from October 7, 2020 (inception) through June 30, 2022 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and after the Initial Public Offering, the search for a target business. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s Sponsor is Frazier Lifesciences Sponsor LLC, a Cayman Islands limited liability company (“Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on December 8, 2020. On December 11, 2020, the Company consummated its Initial Public Offering of 13,800,000 units (each, a “Unit” and collectively, the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), including 1,800,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $138.0 million, and incurring offering costs of approximately $8.1 million, inclusive of approximately $4.8 million in deferred underwriting commissions (See Note 6). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 501,000 units (each, a “Private Placement Unit” and collectively, the “Private Placement Units”), at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of approximately $5.0 million (See Note 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private Placement, approximately $138.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (“Trust Account”) with Continental Stock Transfer &amp; Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> promulgated under the Investment Company Act which will be invested only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding taxes payable on interest earned) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target business or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders of the Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). These Public Shares will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC Topic 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the Amended and Restated Memorandum and Articles of Association which was adopted by the Company at the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 5) prior to this Initial Public Offering (the “Initial Shareholders”) agreed to vote their Founder Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares, private placement shares (the “Private Placement Shares”) underlying the Private Placement Units and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s Sponsor, officers or directors agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company’s obligation to allow the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or December 11, 2022, agreement in principle or definitive agreement for an initial Business Combination within 24 months from the closing of the Initial Public Offering (the “Combination Period”), or (B) with respect to any other provisions relating to shareholders’ rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the redemption of 100% of the Company’s outstanding Public Shares for a portion of the funds held in the Trust Account, each holder will receive a full pro rata portion of the amount then in the Trust Account, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes payable (less taxes payable and up to $100,000 of interest to pay dissolution expenses). The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution in the Trust Account will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the Trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There can be no guarantee that the Company will be successful in obtaining such waivers from its targeted vendors and service providers. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these unaudited condensed financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2022, the Company had approximately $615,000 in its operating bank account, and working capital deficit of approximately $1.1 million. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s liquidity needs to date have been satisfied through a contribution of $25,000 from Sponsor to cover for certain expenses in exchange for the issuance of the Founder Shares, the loan of approximately $83,000 from the Sponsor under the Note (as defined in Note 5), and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company repaid the Note in full on December 14, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 5). As of June 30, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loan. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. However, in connection with the company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after December 11, 2022. The condensed financial statements do not include any adjustment that might be necessary if the company is unable to continue as a going concern. Management intends to complete the Business Combination prior to the liquidation date. </div> 13800000 1800000 10 138000000 8100000 4800000 501000 10 5000000 138000000 10 P185D 0.80 0.50 10 5000001 0.15 1 P24M 100000 100000 10 615000 1100000 25000 83000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 2—Summary of Significant Accounting Policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022, or any future period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed by the Company with the SEC on March 25, 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section 102(b)(1) of the Jumpstart our Business Startups Act of 2021 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.​​​​​​​ </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2022 and December 31, 2021. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in the Trust Account </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheets, primarily due to their short-term nature, except for the derivative warrant liabilities (see Note 8). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities are expensed as incurred, presented as other expenses in the statement of operations. Offering costs associated with the Public Shares were charged against the carrying value of the Class A ordinary shares subject to redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Warrant Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-15</div> “Derivatives and Hedging-Embedded Derivatives” (“ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-15”).</div> The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessed</div> at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (as defined in Note 4) are recognized as derivative liabilities in accordance with “Derivatives and Hedging-Contracts in Entity’s Own Equity” (“ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40”).</div> Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and have subsequently been measured based on the listed market price of such warrants. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, respectively, outside of the shareholders’ deficit section of the Company’s balance sheets. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. This presentation assumes a business combination as the most likely outcome. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the over-allotment) and the Private Placement Warrants to purchase an aggregate of 4,767,000 Class A ordinary shares in the calculation of diluted income per share, because their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the three and six months ended June 30, 2022 and 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> <br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width:60%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per ordinary share:</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Allocation of net loss</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(944,930</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(227,957</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,046,766</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(252,524</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Denominator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal;"><br/></div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Basic and diluted weighted average ordinary shares outstanding</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per ordinary share</div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 1px;"> <td/> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Six Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net income per ordinary share:</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Allocation of net income</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">170,584</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">41,152</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,223,610</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">295,186</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 3.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-style: normal; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"><br/></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Denominator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Basic and diluted weighted average ordinary shares outstanding</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net income per ordinary share</div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.01</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.01</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.09</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.09</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Issued Accounting Standards </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03,</div> ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the condensed financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying condensed financial statements. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022, or any future period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed by the Company with the SEC on March 25, 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section 102(b)(1) of the Jumpstart our Business Startups Act of 2021 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.​​​​​​​ </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2022 and December 31, 2021. </div> 0 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in the Trust Account </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income from investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. </div> P185D P185D <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div> 250000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheets, primarily due to their short-term nature, except for the derivative warrant liabilities (see Note 8). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities are expensed as incurred, presented as other expenses in the statement of operations. Offering costs associated with the Public Shares were charged against the carrying value of the Class A ordinary shares subject to redemption upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Warrant Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-15</div> “Derivatives and Hedging-Embedded Derivatives” (“ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-15”).</div> The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessed</div> at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (as defined in Note 4) are recognized as derivative liabilities in accordance with “Derivatives and Hedging-Contracts in Entity’s Own Equity” (“ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40”).</div> Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and have subsequently been measured based on the listed market price of such warrants. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 13,800,000 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, respectively, outside of the shareholders’ deficit section of the Company’s balance sheets. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div> 13800000 13800000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </div> 0 0 0 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. This presentation assumes a business combination as the most likely outcome. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the over-allotment) and the Private Placement Warrants to purchase an aggregate of 4,767,000 Class A ordinary shares in the calculation of diluted income per share, because their exercise is contingent upon future events. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the three and six months ended June 30, 2022 and 2021. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> <br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width:60%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per ordinary share:</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Allocation of net loss</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(944,930</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(227,957</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,046,766</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(252,524</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Denominator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal;"><br/></div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Basic and diluted weighted average ordinary shares outstanding</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per ordinary share</div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 1px;"> <td/> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Six Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net income per ordinary share:</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Allocation of net income</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">170,584</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">41,152</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,223,610</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">295,186</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 3.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-style: normal; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"><br/></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Denominator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Basic and diluted weighted average ordinary shares outstanding</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net income per ordinary share</div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.01</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.01</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.09</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.09</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 4767000 <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per ordinary share for each class of ordinary shares: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> <br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width:60%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per ordinary share:</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Allocation of net loss</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(944,930</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(227,957</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,046,766</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(252,524</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">) </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Denominator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal;"><br/></div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Basic and diluted weighted average ordinary shares outstanding</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per ordinary share</div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(0.07</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 1px;"> <td/> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Six Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net income per ordinary share:</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Allocation of net income</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">170,584</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">41,152</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,223,610</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">295,186</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 3.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; font-style: normal; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"><br/></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 3.5pt; font-size: 3.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; font-size: 3.5pt; line-height: 3.5pt;"><div style="font-size:3.5pt;;display:inline;"> </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Denominator:</div></div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Basic and diluted weighted average ordinary shares outstanding</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14,301,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,450,000</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt; background-color: rgb(255, 255, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net income per ordinary share</div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.01</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.01</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.09</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">0.09</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> -944930 -227957 -1046766 -252524 14301000 14301000 3450000 3450000 14301000 14301000 3450000 3450000 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 170584 41152 1223610 295186 14301000 14301000 3450000 3450000 14301000 14301000 3450000 3450000 0.01 0.01 0.01 0.01 0.09 0.09 0.09 0.09 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Issued Accounting Standards </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03,</div> ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the condensed financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying condensed financial statements. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 3—Initial Public Offering </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 11, 2020, the Company consummated its Initial Public Offering of 13,800,000 Units, including 1,800,000 Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $138.0 million, and incurring offering costs of approximately $8.1 million, inclusive of approximately $4.8 million in deferred underwriting commissions. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Unit consists of one Class A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one Public Warrant. Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 7). </div> 13800000 1800000 10 138000000 8100000 4800000 11.5 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 4—Private Placement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 501,000 Private Placement Units, at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of approximately $5.0 million. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Private Placement Unit consists of one Class A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant. Each whole private placement warrant underlying the Private Placement Units (the “Private Placement Warrants”) is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Units will expire worthless. The Private Placement Warrants will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> except as described below in Note 7 and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units until 30 days after the completion of the initial Business Combination. </div> 501000 10 5000000 11.5 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 5—Related Party Transactions </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 7, 2020, the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 2,875,000 Class B ordinary shares (the “Founder Shares”). On November 20, 2020, the Sponsor transferred 30,000 Founder Shares to each of the directors other than the Chairman. On December 8, 2020, the Company effected a share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division,</div> resulting in an increase in the total number of Founder Shares outstanding from 2,875,000 to 3,450,000 shares. All shares and associated amounts have been retroactively restated to reflect the share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division.</div> The Sponsor agreed to forfeit up to an aggregate of 450,000 Founder Shares to the extent that the option to purchase additional units was not exercised in full by the underwriters so that the Founder Shares would represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters fully exercised the over-allotment option on December 11, 2020; thus, these Founder Shares were no longer subject to forfeiture. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Loans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 7, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and due upon the closing of the Initial Public Offering. The Sponsor paid an aggregate of approximately $83,000 to cover for the Company’s expenses under the Note. On December 14, 2020, the Company fully repaid the Note. The facility is no longer available to be drawn. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into private placement units of the post Business Combination entity at a price of $10.00 per unit. The private placement units would be identical to the public units sold, subject to certain limited exceptions. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of June 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans. </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Administrative Services Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement that provided that, commencing on the date that the Company’s securities were first listed on the Nasdaq through the earlier of consummation of the initial Business Combination and the liquidation, the Company agreed to pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to the Company. During the three months ended June 30, 2022 and 2021, the Company incurred approximately $30,000 for expenses in connection with the Administrative Services Agreement. During the six months ended June 30, 2022 and 2021, the Company incurred approximately $60,000 for expenses in connection with the Administrative Services Agreement. As of June 30, 2022 and December 31, 2021, we had no amounts payable for such services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, officers or directors, or the Company’s or their affiliates. Any such payments prior to an initial Business Combination will be made from funds held outside the Trust Account. </div> 25000 2875000 30000 2875000 3450000 450000 0.20 12 300000 83000 1500000 10 0 0 10000 30000 30000 60000 60000 0 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 6—Commitments and Contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Registration and Shareholder Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Founder Shares, Private Placement Units, Private Placement Shares, Private Placement Warrants, Class A ordinary shares underlying the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company granted the underwriters a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> option from the date of the prospectus relating to the Initial Public Offering to purchase up to 1,800,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. The underwriters fully exercised the over-allotment option on December 11, 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to an underwriting discount of $0.20 per unit, or approximately $2.8 million in the aggregate, which was paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $4.8 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div> 1800000 0.2 2800000 0.35 4800000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 7—Class A Ordinary Shares Subject To Possible Redemption </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 479,000,000 ordinary shares with a par value of $0.0001 per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. As of June 30, 2022 and December 31, 2021, there were 14,301,000 Class A ordinary shares issued and outstanding, of which 13,800,000 shares were subject to possible redemption have been classified as temporary equity. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:82%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross proceeds</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 138,000,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of Public Warrants at issuance</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,682,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Offering costs allocated to Class A ordinary shares subject to possible redemption</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,653,636</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accretion on Class A ordinary shares subject to possible redemption amount</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,335,636</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Accretion on Class A ordinary shares subject to possible redemption, December 31, 2021</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,000,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase in redemption value of Class A ordinary shares subject to possible redemption</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,977</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class A ordinary shares subject to possible redemption, June 30, 2022</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,032,977</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 479000000 479000000 0.0001 one vote 14301000 13800000 13800000 13800000 13800000 13800000 13800000 13800000 13800000 <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:82%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross proceeds</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 138,000,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of Public Warrants at issuance</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,682,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Offering costs allocated to Class A ordinary shares subject to possible redemption</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,653,636</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accretion on Class A ordinary shares subject to possible redemption amount</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,335,636</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Accretion on Class A ordinary shares subject to possible redemption, December 31, 2021</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,000,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase in redemption value of Class A ordinary shares subject to possible redemption</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,977</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class A ordinary shares subject to possible redemption, June 30, 2022</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,032,977</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"/> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 138000000 -7682000 -7653636 15335636 138000000 32977 138032977 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 8—Derivative Warrant Liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2022 and December 31, 2021, the Company has 4,600,000 and 167,000 Public Warrants and Private Placement Warrants, respectively, outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under certain circumstances). The Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by the Initial Shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-trading</div> day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price (and the $10.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price see “Redemption of warrants for cash when the price per class A ordinary share equals or exceeds $18.00” and “Redemption of warrants for Class A ordinary shares when the price per class A ordinary share equals or exceeds $10.00” as described below). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except (i) that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (ii) except as described below, the Private Placement Warrants will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> so long as they are held by the Sponsor or such its permitted transferees and (iii) the Sponsor or its permitted transferees will have the option to exercise the Private Placement Warrants on a cashless basis and have certain registration rights. If the Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by such holders on the same basis as the Public Warrants. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00: </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the outstanding warrants for redemption (except as described herein with respect to the Private Placement Warrants): </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at a price of $0.01 per warrant; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the last reported sales price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”). </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. If and when the warrants become redeemable by the Company, it may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00: </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the warrants become exercisable, the Company may redeem the outstanding warrants: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part;</div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of Class A ordinary shares to be determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted per share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and</div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), then the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder’s ability to cashless exercise its warrants) as the outstanding Public Warrants as described above. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The “fair market value” of Class A ordinary shares for the above purpose shall mean the volume weighted average price of Class A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div> 4600000 167000 11.5 P5Y 9.2 0.60 9.2 1.15 18 1.80 10 18 10 18 0.01 18 10 0.1 10 18 0.361 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9—Shareholders’ Deficit </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares </div></div></div></div>- The Company is authorized to issue <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,000,000</div></div> preference shares with a par value of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.0001</div></div> per share. At June 30, 2022 and December 31, 2021, there were <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">no</div></div></div></div> preference shares issued or outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> A Ordinary Shares </div></div></div></div>- The Company is authorized to issue <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">479,000,000</div></div> Class A ordinary shares with a par value of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.0001</div></div> per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,301,000</div></div> Class A ordinary shares issued and outstanding, of which <div style="letter-spacing: 0px; top: 0px;;display:inline;">13,800,000</div> shares were subject to possible redemption have been classified as temporary equity (see Note 7). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> B Ordinary Shares </div></div></div></div>- The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. On October 7, 2020, the Company issued 2,875,000 Class B ordinary shares. On December 8, 2020, the Company effected a share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division,</div> resulting in an increase in the total number of Class B ordinary shares outstanding from 2,875,000 to 3,450,000 shares. All shares and associated amounts have been retroactively restated to reflect the share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-division.</div> Of the 3,450,000 Class B ordinary shares outstanding, up to 450,000 shares were subject to forfeiture, to the Company by the Initial Shareholders for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the Initial Shareholders would collectively own 20% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering (excluding the Private Placement Shares and assuming the initial shareholders do not purchase any units in the Initial Public Offering). The underwriters fully exercised the over-allotment option on December 11, 2020; thus, these 450,000 Class B ordinary shares were no longer subject to forfeiture. At June 30, 2022 and December 31, 2021, there were <div style="letter-spacing: 0px; top: 0px;;display:inline;">3,450,000</div> Class B ordinary shares issued and outstanding period. Class A and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the appointment of directors. Holders of the Public Shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason. The provisions of the Amended and Restated Memorandum and Articles of Association governing the appointment or removal of directors prior to the initial Business Combination may only be amended by a special resolution passed by holders representing at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the issued and outstanding Class B ordinary shares. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i) the total number of ordinary shares (excluding the Private Placement Shares) issued and outstanding upon the consummation of the Initial Public Offering, plus (ii) the sum of the total number of Class A ordinary shares issued </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination (net of any redemptions of Class A ordinary shares by Public Shareholders), excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Units issued to the Sponsor, members of the founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one.</div></div></div> 1000000 1000000 0.0001 0.0001 0 0 0 0 479000000 479000000 479000000 479000000 0.0001 0.0001 0.0001 0.0001 14301000 14301000 14301000 14301000 13800000 13800000 20000000 20000000 0.0001 0.0001 2875000 2875000 3450000 3450000 450000 0.20 450000 450000 3450000 3450000 3450000 3450000 0.20 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 10—Fair Value Measurements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2022</div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:71%"/> <td style="vertical-align: bottom; width: 3%;"/> <td/> <td/> <td/> <td style="vertical-align: bottom; width: 3%;"/> <td/> <td/> <td/> <td style="vertical-align: bottom; width: 3%;"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in<br/> Active Markets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments held in Trust Account</div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,132,977</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative warrant liabilities</div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0pt 5pt 0pt 0pt;;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381,360</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2021</div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:71%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in<br/> Active Markets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments held in Trust Account</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,017,009</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative warrant liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,714,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,530</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants of $7,084,000 transferred from a Level 3 measurement to a Level 1 fair value measurement in January 2021, when the Public Warrants were separately listed and traded. The estimated fair value of the Private Warrants of $257,180 was transferred from a Level 3 measurement to a Level 2 fair value measurement in January 2021, as the transfer of Private Placement Warrants to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of Public Warrants was transferred from a Level 1 measurement to a Level 2 measurement due to lack of trading activity as of June 30, 2022. There were no other transfers to/from Levels 1, 2, and 3 during the six months ended June 30, 2022. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three and six months ended June 30, 2022, the Company recognized a gain in the unaudited condensed statements of operations resulting from a decrease in fair value of the derivative warrant liabilities of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">715,000</div> and $<div style="letter-spacing: 0px; top: 0px;;display:inline;">2.4</div> million, respectively, presented as change in fair value of derivative warrant liabilities in the accompanying unaudited condensed statements of operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 1 instruments include investments in mutual funds invested in government securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2022</div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:71%"/> <td style="vertical-align: bottom; width: 3%;"/> <td/> <td/> <td/> <td style="vertical-align: bottom; width: 3%;"/> <td/> <td/> <td/> <td style="vertical-align: bottom; width: 3%;"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in<br/> Active Markets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments held in Trust Account</div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,132,977</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative warrant liabilities</div></td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0pt 5pt 0pt 0pt;;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381,360</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 3%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">December 31, 2021</div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:71%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in<br/> Active Markets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investments held in Trust Account</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,017,009</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative warrant liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,714,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,530</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table> 138132977 0 0 0 381360 0 138017009 0 0 2714000 98530 0 7084000 257180 -715000 -2400000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 11—Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events and transactions that occurred up to the date the unaudited condensed financial statements were issued. Based upon this review, except for as noted below, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On July 25, 2022, the Company entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among the Company, NewAmsterdam Pharma Company B.V., a private company with limited liability (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">besloten vennootschap met beperkte aansprakelijkheid</div></div>) incorporated under the laws of the Netherlands (“Holdco”), NewAmsterdam Pharma Holding B.V., a private company with limited liability (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">besloten vennootschap met beperkte aansprakelijkheid</div></div>) incorporated under the laws of the Netherlands (“NewAmsterdam Pharma”) and NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company (“Merger Sub”). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Concurrently with the execution of the Business Combination Agreement, the Company and Holdco entered into subscription agreements with certain investors (collectively, the “PIPE Investors”), pursuant to which, among other things, such PIPE Investors agreed to subscribe for and purchase, and Holdco agreed to issue and sell to such PIPE Investors, 23,460,000 ordinary shares of Holdco, nominal value <div style="letter-spacing: 0px; top: 0px;;display:inline;">EUR 0.12, at $10.00</div> per share (the “PIPE Shares”), for an aggregate of $234,600,000 <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">in gross proceeds (the “PIPE Financing”). The closing of the PIPE Financing is contingent upon, among other things, the substantially concurrent consummation of the Business Combination and related transactions.</div> </div> 23460000 0.12 10 234600000 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 109 170 1 false 31 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://www.frazierlifesciencesacquisition.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Balance Sheets Sheet http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Balance Sheet (Parenthetical) Sheet http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical Condensed Balance Sheet (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Unaudited Condensed Statements of Operations Sheet http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations Unaudited Condensed Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Unaudited Condensed Statements of Changes in Shareholders' Equity Sheet http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity Unaudited Condensed Statements of Changes in Shareholders' Equity Statements 5 false false R6.htm 1006 - Statement - Unaudited Condensed Statement of Cash Flows Sheet http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows Unaudited Condensed Statement of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Description of Organization, Business Operations and Basis of Presentation Sheet http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation Description of Organization, Business Operations and Basis of Presentation Notes 7 false false R8.htm 1008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - Initial Public Offering Sheet http://www.frazierlifesciencesacquisition.com/role/InitialPublicOffering Initial Public Offering Notes 9 false false R10.htm 1010 - Disclosure - Private Placement Sheet http://www.frazierlifesciencesacquisition.com/role/PrivatePlacement Private Placement Notes 10 false false R11.htm 1011 - Disclosure - Related Party Transactions Sheet http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 1012 - Disclosure - Commitments and Contingencies Sheet http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 1013 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption Sheet http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemption Class A Ordinary Shares Subject To Possible Redemption Notes 13 false false R14.htm 1014 - Disclosure - Derivative Warrant Liabilities Sheet http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilities Derivative Warrant Liabilities Notes 14 false false R15.htm 1015 - Disclosure - Shareholders' Deficit Sheet http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficit Shareholders' Deficit Notes 15 false false R16.htm 1016 - Disclosure - Fair Value Measurements Sheet http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 1017 - Disclosure - Subsequent Events Sheet http://www.frazierlifesciencesacquisition.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 1018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 1019 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 1020 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption (Tables) Sheet http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionTables Class A Ordinary Shares Subject To Possible Redemption (Tables) Tables http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemption 20 false false R21.htm 1021 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurements 21 false false R22.htm 1022 - Disclosure - Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail) Details 22 false false R23.htm 1023 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Income Per Share (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Income Per Share (Detail) Details 24 false false R25.htm 1025 - Disclosure - Initial Public Offering - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail Initial Public Offering - Additional Information (Detail) Details 25 false false R26.htm 1026 - Disclosure - Private Placement - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail Private Placement - Additional Information (Detail) Details 26 false false R27.htm 1027 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 27 false false R28.htm 1028 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 28 false false R29.htm 1029 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail Class A Ordinary Shares Subject To Possible Redemption - Additional Information (Detail) Details 29 false false R30.htm 1030 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption - Summary Of Class A Ordinary Shares Subject To Possible Redemption (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail Class A Ordinary Shares Subject To Possible Redemption - Summary Of Class A Ordinary Shares Subject To Possible Redemption (Detail) Details 30 false false R31.htm 1031 - Disclosure - Derivative Warrant Liabilities - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail Derivative Warrant Liabilities - Additional Information (Detail) Details 31 false false R32.htm 1032 - Disclosure - Shareholders' Deficit - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail Shareholders' Deficit - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Fair Value Measurements - Summary Of Quantitative Information Regarding Fair Value Measurements (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail Fair Value Measurements - Summary Of Quantitative Information Regarding Fair Value Measurements (Detail) Details 33 false false R34.htm 1034 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 34 false false R35.htm 1035 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 35 false false All Reports Book All Reports d386684d10q.htm d386684dex311.htm d386684dex312.htm d386684dex321.htm d386684dex322.htm flac-20220630.xsd flac-20220630_cal.xml flac-20220630_def.xml flac-20220630_lab.xml flac-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d386684d10q.htm": { "axisCustom": 1, "axisStandard": 12, "contextCount": 109, "dts": { "calculationLink": { "local": [ "flac-20220630_cal.xml" ] }, "definitionLink": { "local": [ "flac-20220630_def.xml" ] }, "inline": { "local": [ "d386684d10q.htm" ] }, "labelLink": { "local": [ "flac-20220630_lab.xml" ] }, "presentationLink": { "local": [ "flac-20220630_pre.xml" ] }, "schema": { "local": [ "flac-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 288, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 34, "keyStandard": 136, "memberCustom": 14, "memberStandard": 16, "nsprefix": "flac", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Private Placement", "role": "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Related Party Transactions", "role": "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Commitments and Contingencies", "role": "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:ClassAOrdinarySharesSubjectToPossibleRedemptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption", "role": "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemption", "shortName": "Class A Ordinary Shares Subject To Possible Redemption", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:ClassAOrdinarySharesSubjectToPossibleRedemptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:DerivativeWarrantLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Derivative Warrant Liabilities", "role": "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilities", "shortName": "Derivative Warrant Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:DerivativeWarrantLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Shareholders' Deficit", "role": "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficit", "shortName": "Shareholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Fair Value Measurements", "role": "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Subsequent Events", "role": "http://www.frazierlifesciencesacquisition.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Balance Sheets", "role": "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption (Tables)", "role": "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionTables", "shortName": "Class A Ordinary Shares Subject To Possible Redemption (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn12_11_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Description of Organization, Business Operations and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireRestrictedInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:TermOfRestrictedInvestments", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "0", "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P04_01_2022To06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Income Per Share (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Income Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn12_11_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Initial Public Offering - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "shortName": "Initial Public Offering - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn12_11_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Private Placement - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail", "shortName": "Private Placement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P04_01_2022To06_30_2022_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis", "decimals": "0", "lang": null, "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "2", "first": true, "lang": null, "name": "flac:UnderwritingDiscountPerUnit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "2", "first": true, "lang": null, "name": "flac:UnderwritingDiscountPerUnit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "shortName": "Class A Ordinary Shares Subject To Possible Redemption - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "flac:ClassAOrdinarySharesSubjectToPossibleRedemptionTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022_CommonClassAMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Balance Sheet (Parenthetical)", "role": "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "shortName": "Condensed Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P12_11_2020To12_11_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Class A Ordinary Shares Subject To Possible Redemption - Summary Of Class A Ordinary Shares Subject To Possible Redemption (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "shortName": "Class A Ordinary Shares Subject To Possible Redemption - Summary Of Class A Ordinary Shares Subject To Possible Redemption (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "0", "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "flac:DerivativeWarrantLiabilitiesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Derivative Warrant Liabilities - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "shortName": "Derivative Warrant Liabilities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "flac:DerivativeWarrantLiabilitiesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Shareholders' Deficit - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail", "shortName": "Shareholders' Deficit - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "2", "lang": null, "name": "flac:PercentOfSharesConvertible", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_InvestmentsHeldInTrustAccountMemberusgaapFinancialInstrumentAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Fair Value Measurements - Summary Of Quantitative Information Regarding Fair Value Measurements (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail", "shortName": "Fair Value Measurements - Summary Of Quantitative Information Regarding Fair Value Measurements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_InvestmentsHeldInTrustAccountMemberusgaapFinancialInstrumentAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "flac:FairValueOfPublicWarrants", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P07_25_2022To07_25_2022_PipeSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Subsequent Events - Additional Information (Detail)", "role": "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail", "shortName": "Subsequent Events - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P07_25_2022To07_25_2022_PipeSharesMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P04_01_2022To06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Unaudited Condensed Statements of Operations", "role": "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations", "shortName": "Unaudited Condensed Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P04_01_2022To06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Unaudited Condensed Statements of Changes in Shareholders' Equity", "role": "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "shortName": "Unaudited Condensed Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P04_01_2022To06_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Unaudited Condensed Statement of Cash Flows", "role": "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows", "shortName": "Unaudited Condensed Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInPrepaidExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - Description of Organization, Business Operations and Basis of Presentation", "role": "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation", "shortName": "Description of Organization, Business Operations and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Initial Public Offering", "role": "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d386684d10q.htm", "contextRef": "P01_01_2022To06_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "flac:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 31, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "flac_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting policies.", "label": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "flac_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting policies.", "label": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "flac_AdministrationAndSupportServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administration And Support Services [Member]", "label": "Administration And Support Services [Member]", "terseLabel": "Administration And Support Services [Member]" } } }, "localname": "AdministrationAndSupportServicesMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_AgreedAmountToRepayForAdministrativeServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Agreed amount to repay for administrative services.", "label": "Agreed Amount To Repay For Administrative Services", "terseLabel": "Agreed amount to repay for administrative services" } } }, "localname": "AgreedAmountToRepayForAdministrativeServices", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "flac_ClassACommonStockAndOneThirdOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A common stock and one third of one redeemable warrant.", "label": "Class A Common Stock And One Third Of One Redeemable Warrant [Member]", "terseLabel": "Class A Common Stock And One Third Of One Redeemable Warrant", "verboseLabel": "Class A Common Stock and One Third of One Redeemable Warrant [Member]" } } }, "localname": "ClassACommonStockAndOneThirdOfOneRedeemableWarrantMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_ClassACommonStockSubjectToPossibleRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A common stock subject to possible redemption.", "label": "Class A Common Stock Subject To Possible Redemption [Member]", "verboseLabel": "Class A Common Stock Subject to Possible Redemption [Member]" } } }, "localname": "ClassACommonStockSubjectToPossibleRedemptionMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_ClassAOrdinarySharesSubjectToPossibleRedemptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class a Ordinary Shares Subject To Possible Redemption.", "label": "Class a Ordinary Shares Subject To Possible Redemption [Text Block]", "terseLabel": "Class A Ordinary Shares Subject To Possible Redemption" } } }, "localname": "ClassAOrdinarySharesSubjectToPossibleRedemptionTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemption" ], "xbrltype": "textBlockItemType" }, "flac_CommonStockSharesIssuedIncludingTemporaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares issued including temporary equity.", "label": "Common Stock Shares Issued Including Temporary Equity", "terseLabel": "Common stock shares issued including temporary equity" } } }, "localname": "CommonStockSharesIssuedIncludingTemporaryEquity", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "flac_CommonStockSharesOutstandingIncludingTemporaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares outstanding including temporary equity.", "label": "Common Stock Shares Outstanding Including Temporary Equity", "terseLabel": "Common stock shares outstanding including temporary equity" } } }, "localname": "CommonStockSharesOutstandingIncludingTemporaryEquity", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "flac_DeferredUnderwritingCommissionsPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commissions per unit.", "label": "Deferred Underwriting Commissions Per Unit", "terseLabel": "Deferred underwriting commissions per unit" } } }, "localname": "DeferredUnderwritingCommissionsPerUnit", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "flac_DerivativeWarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Abstract]" } } }, "localname": "DerivativeWarrantLiabilitiesAbstract", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "xbrltype": "stringItemType" }, "flac_DerivativeWarrantLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Line Items]" } } }, "localname": "DerivativeWarrantLiabilitiesLineItems", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_DerivativeWarrantLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Member]" } } }, "localname": "DerivativeWarrantLiabilitiesMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "flac_DerivativeWarrantLiabilitiesNonCurrent": { "auth_ref": [], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative warrant liabilities non current.", "label": "Derivative Warrant Liabilities Non Current", "terseLabel": "Derivative warrant liabilities" } } }, "localname": "DerivativeWarrantLiabilitiesNonCurrent", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "flac_DerivativeWarrantLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Table]" } } }, "localname": "DerivativeWarrantLiabilitiesTable", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_DerivativeWarrantLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative warrant liabilities.", "label": "Derivative Warrant Liabilities [Text Block]", "terseLabel": "Derivative Warrant Liabilities" } } }, "localname": "DerivativeWarrantLiabilitiesTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilities" ], "xbrltype": "textBlockItemType" }, "flac_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging growth company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flac_FairValueOfNetAssetsOfTheAcquireAsAPercentageOfAssetsInTheTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of net assets of the acquire as a percentage of assets in the trust account.", "label": "Fair Value Of Net Assets Of The Acquire As A Percentage Of Assets In The Trust Account", "terseLabel": "Fair value of net assets of the acquire as a percentage of assets in the trust account" } } }, "localname": "FairValueOfNetAssetsOfTheAcquireAsAPercentageOfAssetsInTheTrustAccount", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_FairValueOfPrivateWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of private warrants.", "label": "Fair value of private warrants" } } }, "localname": "FairValueOfPrivateWarrants", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "flac_FairValueOfPublicWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of public warrants.", "label": "Fair Value Of Public Warrants", "terseLabel": "Fair value of public warrants" } } }, "localname": "FairValueOfPublicWarrants", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "flac_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares.", "label": "Founder Shares [Member]", "terseLabel": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_GaapFinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GAAP Financial Instrument [Axis]", "label": "GAAP Financial Instrument [Axis]" } } }, "localname": "GaapFinancialInstrumentAxis", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_GaapFinancialInstrumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GAAP Financial Instrument [Domain]", "label": "GAAP Financial Instrument [Domain]" } } }, "localname": "GaapFinancialInstrumentDomain", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Abstract]" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "xbrltype": "stringItemType" }, "flac_InitialPublicOfferingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Line Items]" } } }, "localname": "InitialPublicOfferingLineItems", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_InitialPublicOfferingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Table]" } } }, "localname": "InitialPublicOfferingTable", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Text Block]", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "flac_InvestmentsHeldInTrustAccountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Held in Trust Account [Member]" } } }, "localname": "InvestmentsHeldInTrustAccountMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "flac_MinimumPerShareAmountToBeMaintainedInTheTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum per share amount to be maintained in the trust account.", "label": "Minimum Per Share Amount To Be Maintained In The Trust Account", "terseLabel": "Minimum per share amount to be maintained in the trust account" } } }, "localname": "MinimumPerShareAmountToBeMaintainedInTheTrustAccount", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "flac_NetWorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net working capital.", "label": "Net Working Capital", "terseLabel": "Net working capital" } } }, "localname": "NetWorkingCapital", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "flac_NumberOfSharesForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares forfeited.", "label": "Number Of Shares Forfeited", "terseLabel": "Number of shares forfeited" } } }, "localname": "NumberOfSharesForfeited", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "flac_NumberOfSharesNoLongerSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares no longer subject to forfeiture.", "label": "Number Of Shares No Longer Subject To Forfeiture", "terseLabel": "Number of shares no longer subject to forfeiture" } } }, "localname": "NumberOfSharesNoLongerSubjectToForfeiture", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "flac_NumberOfSharesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares transferred.", "label": "Number Of Shares Transferred", "terseLabel": "Number of shares transferred" } } }, "localname": "NumberOfSharesTransferred", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "flac_OfferingCostsAllocatedToClassACommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs allocated to class A common stock subject to possible redemption.", "label": "Offering Costs Allocated To Class A Common Stock Subject To Possible Redemption", "verboseLabel": "Class A ordinary share issuance costs" } } }, "localname": "OfferingCostsAllocatedToClassACommonStockSubjectToPossibleRedemption", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "monetaryItemType" }, "flac_OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering costs associated with initial public offering.", "label": "Offering Costs Associated With Initial Public Offering [Policy Text Block]", "terseLabel": "Offering Costs Associated with the Initial Public Offering" } } }, "localname": "OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flac_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_PercentOfExercisePriceOfTheWarrantsAdjustedToSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of exercise price of the warrants adjusted to share price.", "label": "Percent Of Exercise Price Of The Warrants Adjusted To Share Price", "terseLabel": "Percent of exercise price of the warrants adjusted to share price" } } }, "localname": "PercentOfExercisePriceOfTheWarrantsAdjustedToSharePrice", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_PercentOfFounderSharesToIssuedAndOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of founder shares to issued and outstanding shares.", "label": "Percent Of Founder Shares To Issued And Outstanding Shares", "terseLabel": "Percent of founder shares to issued and outstanding shares" } } }, "localname": "PercentOfFounderSharesToIssuedAndOutstandingShares", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_PercentOfGrossProceedsFromSuchIssuancesToTotalEquityProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of gross proceeds from such issuances to total equity proceeds.", "label": "Percent Of Gross Proceeds From Such Issuances To Total Equity Proceeds", "terseLabel": "Percent of gross proceeds from such issuances to total equity proceeds" } } }, "localname": "PercentOfGrossProceedsFromSuchIssuancesToTotalEquityProceeds", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_PercentOfSharesConvertible": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of shares convertible.", "label": "Percent Of Shares Convertible", "terseLabel": "Percent of shares convertible" } } }, "localname": "PercentOfSharesConvertible", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of public shares to be redeemed in case business combination is not consummated.", "label": "Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated", "terseLabel": "Percentage of public shares to be redeemed in case business combination is not consummated" } } }, "localname": "PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_PercentageOfSharesEligibleToBeTransferredWithoutAnyRestriction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares eligible to be transferred without any restriction.", "label": "Percentage Of Shares Eligible To Be Transferred Without Any Restriction", "terseLabel": "Percentage of shares eligible to be transferred without any restriction" } } }, "localname": "PercentageOfSharesEligibleToBeTransferredWithoutAnyRestriction", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "flac_PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period within which business combination shall be consummated from the date of initial public offer.", "label": "Period Within Which Business Combination Shall Be Consummated From The Date Of Initial Public Offer", "terseLabel": "Period within which business combination shall be consummated from the date of initial public offer" } } }, "localname": "PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffer", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "flac_PipeSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PIPE shares.", "label": "PIPE Shares [Member]" } } }, "localname": "PipeSharesMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_PrivatePlacementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement.", "label": "Private Placement [Abstract]" } } }, "localname": "PrivatePlacementAbstract", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "xbrltype": "stringItemType" }, "flac_PrivatePlacementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement.", "label": "Private Placement [Line Items]" } } }, "localname": "PrivatePlacementLineItems", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_PrivatePlacementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement.", "label": "Private Placement [Table]" } } }, "localname": "PrivatePlacementTable", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_PrivatePlacementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement.", "label": "Private Placement [Text Block]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "flac_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement warrants.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants [Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_RecentlyIssuedAccountingStandardsButNotYetEffectivePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently issued accounting standards but not yet effective.", "label": "Recently Issued Accounting Standards But Not Yet Effective [Policy Text Block]", "terseLabel": "Recent Issued Accounting Standards" } } }, "localname": "RecentlyIssuedAccountingStandardsButNotYetEffectivePolicyTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flac_RelatedPartyLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party loan.", "label": "Related Party Loan [Member]", "terseLabel": "Related Party Loan [Member]" } } }, "localname": "RelatedPartyLoanMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_RestrictedInvestmentValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted investment value per share.", "label": "Restricted Investment Value Per Share", "terseLabel": "Restricted investment value per share" } } }, "localname": "RestrictedInvestmentValuePerShare", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "flac_ShareTriggerPriceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Trigger Price One [Member]", "terseLabel": "Share Trigger Price One [Member]" } } }, "localname": "ShareTriggerPriceOneMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_ShareTriggerPriceThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Trigger Price Three [Member]", "terseLabel": "Share Trigger Price Three [Member]" } } }, "localname": "ShareTriggerPriceThreeMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_ShareTriggerPriceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Trigger Price Two [Member]", "terseLabel": "Share Trigger Price Two [Member]" } } }, "localname": "ShareTriggerPriceTwoMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_TemporaryEquityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity.", "label": "Temporary Equity [Policy Text Block]", "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption" } } }, "localname": "TemporaryEquityPolicyTextBlock", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flac_TemporaryEquitySharesSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Shares Subject To Possible Redemption", "label": "Temporary Equity Shares Subject To Possible Redemption", "terseLabel": "Temporary Equity Shares Subject To Possible Redemption" } } }, "localname": "TemporaryEquitySharesSubjectToPossibleRedemption", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "flac_TermOfRestrictedInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of restricted investments.", "label": "Term Of Restricted Investments", "terseLabel": "Term of restricted investments" } } }, "localname": "TermOfRestrictedInvestments", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "flac_TriggerPriceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trigger Price [Axis]" } } }, "localname": "TriggerPriceAxis", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "flac_TriggerPriceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trigger Price [Domain]" } } }, "localname": "TriggerPriceDomain", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "flac_UnderwritingDiscountPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting discount per unit.", "label": "Underwriting Discount Per Unit", "terseLabel": "Underwriting discount per unit" } } }, "localname": "UnderwritingDiscountPerUnit", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "flac_UnderwritingDiscountValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Underwriting discount value.", "label": "Underwriting Discount Value", "terseLabel": "Underwriting discount value" } } }, "localname": "UnderwritingDiscountValue", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "flac_WeightedaveragenumberofsharesoutstandingbasicanddilutedabstractAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract", "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedaveragenumberofsharesoutstandingbasicanddilutedabstractAbstract", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "flac_WorkingCapitalLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loan.", "label": "Working Capital Loan [Member]", "terseLabel": "Working Capital Loan [Member]" } } }, "localname": "WorkingCapitalLoanMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20220630", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r136", "r138", "r139", "r140", "r158", "r185", "r219", "r220", "r298", "r299", "r300", "r301", "r302", "r303", "r322", "r342", "r343", "r359", "r360" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r130", "r136", "r138", "r139", "r140", "r158", "r185", "r209", "r219", "r220", "r222", "r223", "r224", "r298", "r299", "r300", "r301", "r302", "r303", "r322", "r342", "r343", "r359", "r360" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r130", "r136", "r138", "r139", "r140", "r158", "r185", "r209", "r219", "r220", "r222", "r223", "r224", "r298", "r299", "r300", "r301", "r302", "r303", "r322", "r342", "r343", "r359", "r360" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r23", "r59", "r282", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts Payable, Related Parties, Current" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r63", "r64", "r65", "r225", "r226", "r227", "r253" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r199", "r206" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Adjustments to additional paid in capital stock issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from the computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r58", "r102", "r104", "r108", "r117", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r239", "r241", "r267", "r286", "r288", "r325", "r334" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r22", "r58", "r117", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r239", "r241", "r267", "r286", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Cash held in Trust Account" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Investments held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.", "label": "Capital Units [Member]", "terseLabel": "Units, each consisting of one Class A ordinary share and one-third of a Warrant to acquire one Class A ordinary share [Member]" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r8", "r288", "r349", "r350" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash", "verboseLabel": "Cash at bank" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r51", "r324" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Investments Held in the Trust Account" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r45", "r50", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash\u2014end of the period", "periodStartLabel": "Cash\u2014beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r45", "r268" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash insured with federal depository insurance corporation" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r13", "r14", "r15", "r55", "r58", "r78", "r79", "r80", "r82", "r84", "r90", "r91", "r92", "r117", "r144", "r148", "r149", "r150", "r153", "r154", "r183", "r184", "r188", "r192", "r199", "r267", "r366" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r207", "r221" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Class of warrant or right, exercise price of warrants or rights", "verboseLabel": "Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of Securities Called by Each Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r329", "r339" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r141", "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r63", "r64", "r253" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "verboseLabel": "Common Stock, No Par Value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r95", "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r12", "r327", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Convertible debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r57", "r61", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r174", "r175", "r176", "r177", "r276", "r326", "r327", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r12", "r173", "r327", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28", "r57", "r61", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r174", "r175", "r176", "r177", "r276" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred underwriting commissions" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current and Noncurrent", "terseLabel": "Deferred underwriting commissions value" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r60", "r244", "r245", "r246", "r247", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Warrant Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and diluted net loss per ordinary share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r38", "r68", "r69", "r70", "r71", "r72", "r76", "r78", "r82", "r83", "r84", "r87", "r88", "r254", "r255", "r331", "r341" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share - Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r38", "r68", "r69", "r70", "r71", "r72", "r78", "r82", "r83", "r84", "r87", "r88", "r254", "r255", "r331", "r341" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share - Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) per Ordinary Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r63", "r64", "r65", "r67", "r73", "r75", "r89", "r118", "r199", "r206", "r225", "r226", "r227", "r237", "r238", "r253", "r269", "r270", "r271", "r272", "r273", "r274", "r277", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r48", "r178" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of derivative warrant liabilities", "terseLabel": "Change in fair value of derivative warrant liabilities", "verboseLabel": "Proceeds allocated to public warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r256", "r257", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r256", "r257", "r258", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Summary of quantitative information regarding fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r164", "r174", "r175", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r257", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r256", "r257", "r259", "r260", "r264" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r164", "r210", "r211", "r216", "r218", "r257", "r295" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r164", "r174", "r175", "r210", "r211", "r216", "r218", "r257", "r296" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r164", "r174", "r175", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r257", "r297" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r164", "r174", "r175", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r261", "r264" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability) [Abstract]" } } }, "localname": "FairValueNetAssetLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r172", "r197", "r251", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r366", "r367", "r368", "r369", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r33", "r229", "r230", "r233", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r47" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r40", "r101" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income from investments held in Trust Account", "verboseLabel": "Interest income from investments held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r58", "r105", "r117", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r240", "r241", "r242", "r267", "r286", "r287" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r58", "r117", "r267", "r288", "r328", "r338" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r27", "r58", "r117", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r240", "r241", "r242", "r267", "r286", "r287", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "verboseLabel": "Derivative warrant liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities": { "auth_ref": [ "r2" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation.", "label": "Liquidation Basis of Accounting, Accrued Costs to Dispose of Assets and Liabilities", "terseLabel": "Expenses payable on liquidation" } } }, "localname": "LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r134", "r135", "r136", "r137", "r138", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MinimumNetWorthRequiredForCompliance": { "auth_ref": [ "r352", "r353", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework.", "label": "Minimum Net Worth Required for Compliance", "verboseLabel": "Minimum net worth necessary to carry out business combination" } } }, "localname": "MinimumNetWorthRequiredForCompliance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r45" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r45", "r46", "r49" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r31", "r32", "r36", "r37", "r49", "r58", "r66", "r68", "r69", "r70", "r71", "r74", "r75", "r81", "r102", "r103", "r106", "r107", "r109", "r117", "r144", "r145", "r146", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r255", "r267", "r330", "r340" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Allocation of net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "verboseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expenses):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r102", "r103", "r106", "r107", "r109" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Organization, Business Operations and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r44" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering costs paid", "verboseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "terseLabel": "Payment to acquire restricted investments" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r183" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r183" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at June 30, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r21", "r128", "r129" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offer", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from related party debt", "verboseLabel": "Proceeds from related party debt" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]" } } }, "localname": "RedeemableNoncontrollingInterestByLegalEntityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Redeemable Noncontrolling Interest [Line Items]" } } }, "localname": "RedeemableNoncontrollingInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r280", "r283" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Due to related party" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r217", "r280", "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Administrative expenses\u2014related party", "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "verboseLabel": "Administrative expenses\u2014related party" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r278", "r279", "r281", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashEquivalents": { "auth_ref": [ "r52", "r324", "r336", "r356", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents", "terseLabel": "Cash equivalents in its operating account" } } }, "localname": "RestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r206", "r288", "r337", "r347", "r348" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r63", "r64", "r65", "r67", "r73", "r75", "r118", "r225", "r226", "r227", "r237", "r238", "r253", "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock issue price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Basic and Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r13", "r14", "r15", "r55", "r90", "r91", "r179", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r192", "r197", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r53", "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r55", "r58", "r78", "r79", "r80", "r82", "r84", "r90", "r91", "r92", "r117", "r144", "r148", "r149", "r150", "r153", "r154", "r183", "r184", "r188", "r192", "r199", "r267", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r30", "r34", "r35", "r36", "r63", "r64", "r65", "r67", "r73", "r75", "r89", "r118", "r199", "r206", "r225", "r226", "r227", "r237", "r238", "r253", "r269", "r270", "r271", "r272", "r273", "r274", "r277", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r63", "r64", "r65", "r89", "r323" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r199", "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during the period shares", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock issued during period, value, issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r58", "r110", "r117", "r267", "r288" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r56", "r184", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r198", "r206", "r208", "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r275", "r290" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r275", "r290" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r275", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r275", "r290" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "negatedLabel": "Increase in redemption value of Class\u00a0A ordinary shares subject to possible redemption" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "terseLabel": "Accretion of carrying value to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r7", "r180" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r144", "r148", "r149", "r150", "r153", "r154" ], "calculation": { "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Class A ordinary shares subject to possible redemption, $0.0001 par value; 13,800,000 shares issued and outstanding at redemption value of approximately $10.00 per share at June 30, 2022 and December 31, 2021", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "verboseLabel": "Class A ordinary share subject to possible redemption" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r7", "r180" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary equity par or stated value per share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r7", "r180" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Temporary equity redemption price per share" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/DescriptionOfOrganizationBusinessOperationsAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary Equity, Shares Issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "definitionGuidance": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary equity shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/CondensedBalanceSheetParenthetical", "http://www.frazierlifesciencesacquisition.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r7", "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Summary Of Class A Ordinary Shares Subject To Possible Redemption" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/ClassAOrdinarySharesSubjectToPossibleRedemptionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r172", "r197", "r251", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r366", "r367", "r368", "r369", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/FairValueMeasurementsSummaryOfQuantitativeInformationRegardingFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r228", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties on unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r93", "r94", "r96", "r97", "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/CoverPage", "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants and Rights Outstanding, Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/DerivativeWarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r77", "r84" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r76", "r84" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares - Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomePerShareDetail", "http://www.frazierlifesciencesacquisition.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=95464943&loc=SL35686261-199414" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r364": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r365": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r366": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r367": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r368": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r369": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r370": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r371": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r372": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r373": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r374": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" } }, "version": "2.1" } ZIP 54 0001193125-22-218740-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-218740-xbrl.zip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�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end